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3.0 Abstract 
 
3.1 Aim 
The aim of this study is to determine in a randomized control trial the microbiological and 
immunological effect of azithromycin (AZM) in cases of peri-implantitis versus a placebo at 
the peri-implant tissue level in a sample of patients diagnosed with peri-implantitis. 
3.2 Methodology  
17 patients referred to periodontics department at the Westmead Centre for Oral Health for 
the treatment of peri-implantitis were invited to participate in the study. Five subjects with 
healthy implants were also recruited for the immuno-regulatory part of the study to act as 
healthy controls. After clinical assessment, subjects received non-surgical debridement of 
implant/abutment surfaces and oral hygiene instruction. The subjects were then randomly 
assigned to receive AZM (1 x 500mg capsule per day for 3 days) and the controls received 
placebo tablets.  
Submucosal plaque and peri-implant crevicular fluid samples were collected from selected 
implants at the following time points: day 0, 3, 7, 21, 90 and 180 for microbiological and 
immunological analysis. The primary outcome variables were mean counts and mean 
changes from baseline levels in the anaerobic and aerobic microbiological counts (CFU/ml) 
and the proinflammatory cytokine Il-1β levels (pg/ml) over time. Analysis of the species 
associated with peri-implantitis and the cytokine levels of healthy control implants was also 
determined. 
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3.3 Results 
The placebo group showed a trend for aerobic bacteria to steadily rebound after day 7. This 
rebound appeared to be delayed until day 90 in the azithromycin group. Both treatment 
groups showed a trend for the mean anaerobic bacteria count to decrease from day 1 to 7 
after which a gradual increase in counts was observed for the remainder of the study. The 
magnitude of this rebound in anaerobic bacteria levels was greater in the placebo group. 
There were no statistical significant differences observed between the two groups at any 
times points (p>0.05). 
The placebo group showed a mean change from baseline resulting in reduction in anaerobic 
bacteria counts up to day 7, after which a rebound in bacteria levels were observed above 
baseline levels and sustained throughout the remainder of the study. The azithromycin group 
showed mean changes from baseline levels resulting in a sustained decrease in mean 
anaerobic bacteria levels below baseline observed up 180 days. No statistical significant 
differences observed between the two groups at any times points (p>0.05). 
Orange complex species were found in the highest frequency (94.1%) whilst the red complex 
bacteria were found at the lowest frequency (17.6%) with no statistical significant differences 
between treatment groups observed at baseline. 
Both groups demonstrated a trend for mean reduction in IL-1β levels after treatment over time 
which was sustained throughout the study. The magnitude of changes from baseline levels 
appeared greater in the azithromycin group. No statistical significance was observed between 
treatment groups (p>0.05). 
It was observed that the percentage frequency of subjects who were “positive responders” 
was higher in the azithromycin group at all time points. 
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3.4 Conclusion 
The reductions and subsequent recolonization observed in the immunological data closely 
correlated with that of the microbiological data. Despite reductions in levels of IL-1β initially 
after treatment, the levels gradually rebounded throughout the course of the study. 
Throughout all time points, IL-1β did not return to baseline levels, which were likely a result of 
the treatment effect. Similarly, a reduction in microbiological parameters was seen initially 
post therapy with a trend for a gradual rebound in counts seen over time. 
No statistical significant effect was observed between treatment groups despite a trend for a 
greater magnitude change in outcome measures for subjects’ allocated azithromycin. We 
demonstrated that the response to non-surgical treatment, with or without adjunctive 
azithromycin is highly variable and unpredictable with gradual rebound in immunological and 
microbiological parameters seen after 6 months. Because of the limited number of patients 
recruited, no definitive conclusions can be made. There is clear indication that further 
longitudinal research into the effects of azithromycin at peri-implant-host interface is 
warranted. 
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4.0 Introduction 
 
The use of dental implants in today’s dentistry has revolutionized the way we rehabilitate our 
patients in clinical practice. The literature suggests that the use of dental implants after 
appropriate treatment planning can have high survival and success rates with long standing 
predictability. 1, 2 However, it must be realized that even with their ever increasing popularity 
and use in practice, implants are also susceptible to a range of mechanical and biological 
complications. Of the biological complications, peri-implant disease has been the main focus 
of attention over the past decade with peri-implantitis resulting in loss of the supporting 
structures with potential loss of the implant. 
A recent systematic review suggests that the prevalence of peri-implantitis is in the order of 
10% of implants and 20% of subjects affected,3 which indicates the potential burden that this 
problem has and will continue to place on those affected including the dental industry as a 
whole. When one considers the number of implants that have been placed worldwide as well 
as the trend for an increased number to be placed in the future, the profession must be ready 
to manage the increased incidence of biological complications to be expected. 
Upon review of the literature, it becomes evident that despite various clinical 
recommendations or protocols that may help guide us to the treatment of such a condition 
there is still no one protocol that has shown to be superior. This has obvious clinical 
ramifications for those implants and subjects affected as well as those attempting to treat the 
disease. What is clear from the literature is the need for further research into the therapy of 
peri-implantitis and the potential role that adjunctive treatments such as antimicrobials may 
play in this process. 
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5.0 Literature Review 
 
5.1 Definition of peri-implant disease 
 
Peri-implant diseases include peri-implant mucositis which describes inflammation of the peri-
implant mucosa and peri-implantitis which describes inflammation of the mucosa with loss of 
supporting bone. Clinical signs which may be observed include redness, swelling, bleeding 
on probing, suppuration, recession of the mucosa and increased probing depths. 
In susceptible individuals, it has been proposed to be brought about by an inflammatory 
process that is a result of the host response to bacterial contamination. 
 
In 1994, the First European Workshop on Periodontology developed a consensus report with 
regard to clearer definitions of the disease.4 Peri-implant mucositis was defined as a 
reversible inflammation of the soft tissues surrounding an implant in function with no loss of 
supporting bone. Peri-implantitis was defined as an inflammatory process not only affecting 
the soft tissues around a dental implant in function but also including evidence of loss of 
supporting bone. More recently, Zitzmann and Berglundh termed peri-implant disease as a 
collective term for inflammatory reactions in the tissues surrounding an implant. 5 Further to 
this, peri-implant mucositis was defined as the presence of inflammation in the mucosa at an 
implant with no loss of supporting bone (abstaining from using the term reversible for such 
conditions). Peri-implantitis in addition to this inflammation is characterised by loss of 
supporting bone. 
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5.2 Prevalence  
 
There is limited evidence in the literature outlining the prevalence of peri-implant diseases. 
This is further compounded by inconsistencies in the methodologies employed to diagnose 
the condition with many studies using varying definitions of the disease which makes it 
difficult to interpret and draw conclusions of the true prevalence rates. It is clear that there are 
wide differences in the incidence and prevalence of peri-implantitis reported by studies and 
depending on the particular diagnostic criteria used has led to significant variation of the 
reported data. Incidence can be defined as the number of cases over a given time period 
whilst prevalence relies on information gathered from cross sectional studies and relates to 
the number of cases at a given point in time.  A systematic review which analysed implant 
complications over 5 years found an incidence rate in the range of 0 to 14%.2 
 
The following table summarises the literature regarding the prevalence of peri-implantitis. 
 
Table 1. Literature on prevalence of peri-implantitis. 
Author Study type Subjects/Implants Time in 
function 
(mean 
years) 
Prevalence (%) 
Fransson et 
al,6 2005 
Cross 
sectional 
662/3413 5-20 (range) 27.8 subjects 
12.4% implants 
Koldsland et 
al,7 2010 
Cross 
sectional 
109/351 8.4 47.1% subjects 
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36.6% implants 
Marrone et al 
,8 2013 
Cross 
sectional 
103/266 8.5 37% subjects 
23% implants 
Mir- Mari et al 
,9 2012 
Cross 
sectional 
245/964 6.3 16.3% subjects 
9.1% implants 
Renvert et al 
,10 2007 
Cross 
sectional 
213/976 10.8 14.9% subjects 
Rinke et al,11 
2011 
Cross 
sectional 
89/ avg. 3.9 implants 
per subject 
5.7 37% subjects 
23% implants 
Rocuzzo et 
al,12 2010 
Longitudin
al 
101/246 10 Periodontally healthy 
patients – 4.7% 
Moderate periodontally 
compromised patients 
– 11.2% 
Severely periodontally 
compromised patients 
– 15.1% 
Roos-
Jansaker et 
al,13 2006 
Cross 
sectional 
218/999 9-14 (range) 16% subjects 
6.6% implants 
Adapted from the American Academy of Periodontology Academy Report 14. 
 
A recent systematic review analysing the prevalence and incidence of peri-implantitis stated 
that the prevalence of peri-implantitis is in the order of 10% of implants and 20% of patients 
affected during 5-10 years after implant placement.3 Considering the available literature, one 
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can see the problem with applying different disease thresholds for assessment of peri-
implantitis and then trying to extrapolate this to the wide variations seen in reporting. 
Koldsland et al,7 demonstrated this by outlining that the prevalence varied by as much as 
36% depending on the thresholds used. A clear and standardised definition of the disease is 
warranted so that future studies looking at incidence and prevalence are able to give us a 
more accurate report of disease distribution. 
 
5.3 Clinical features 
 
The clinical features of peri-implant mucositis as described by Albrektsson et al,4 in 1994, 
included bleeding and/or suppuration on probing and increased periodontal probing depths 
between 4 to 5mm. 
Clinical signs of peri-implantitis included periodontal probing depths of greater than 5mm, 
bleeding and/or suppuration on probing whilst evidence of bone loss is most often determined 
radiographically. Typically the pattern of bone loss around the affected dental implant formed 
a crater type defect. 
In 2008, the consensus report of the sixth European workshop on Periodontology concluded 
that bleeding on gentle probing will indicate the presence of inflammation in the surrounding 
mucosa and an increase in probing depth over time can be associated with loss of 
attachment and supporting bone. The loss of supporting bone is confirmed utilising 
radiographs.15 Along with suppuration, these are the most frequent clinical features of peri-
implantitis. 
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5.4 Aetiology 
5.4.1 Biofilm Structure 
 
In nature, bacteria grow in complex polymicrobial associations attached to surfaces known as 
biofilms. Acknowledging the complex nature of biofilms is paramount in not only 
understanding a key pathological feature of peri-implant conditions but also in the treatment 
modalities aimed at controlling the condition. The biofilm acts to recruit other bacteria to its 
community and contributes to the array of metabolically diverse bacteria present. This 
variability aims to protect specific species that may be more susceptible to antimicrobial 
agents by allowing their colonization further away from the hostile host environment whilst 
positioning more resistant organisms in closer proximity to these outer surfaces.16 The biofilm 
also functions to regulate the behaviour of its community by a process called quorum 
sensing. This is a form of cell to cell communication which gives the biofilm several 
advantages. For example, by allowing transfer of genetic material between species, up 
regulation of adherence molecules can be instituted allowing a more effective and efficient 
attachment to biological surfaces. Such metabolic co-operation between species can also 
enable the community to utilize food sources more efficiently. That is, the metabolic waste of 
one species can be used as energy for another. This cooperation gives the community a 
significant advantage over the host. Importantly, these biofilms often display resistance to 
antimicrobials. It is proposed that this resistance is brought about by an inability of the 
antimicrobial agent to penetrate through the biofilm itself or because of the slow growing sub 
populations of bacteria present are more likely to develop resistance to these agents.17 
 The microbiota implicated in the periodontal disease process is complicated with over 500 
bacterial species having  been detected thus far in the biofilm,18 one therefore has to 
appreciate this complexity when undertaking in the treatment of such disease processes. 
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Biofilms will rapidly form around the transmucosal part of the implant once exposed to the 
oral environment. The biofilm development around teeth and implants was shown to be 
remarkably similar after 3 weeks of plaque accumulation with similar proportions of coccoid 
species, motile rods and spirochetes observed.19 
The development of biofilms on the surface of implants recently exposed (via abutment 
connection) to the oral cavity was examined by Quirynen et al.20 Plaque samples were taken 
from implant and teeth sites at various time intervals and evaluated using checkerboard DNA-
DNA hybridisation techniques. They showed that the bacteria associated with periodontitis 
could colonize peri-implant pockets within a week. They also demonstrated that the so called 
early colonising species associated with biofilm formation of teeth, appeared on implants 
within 2 weeks and were maintained there for the remainder of the study. These studies 
indicate that the early development of biofilms on implant surfaces was similar to that seen on 
teeth.  Further to this, De Boever et al examined 22 subjects previously treated for aggressive 
periodontitis in which 68 implants were placed in a non-submerged fashion.21 They observed 
that the implants were colonized by their five targeted periodontal pathogens as early as 10 
days after implant placement and an increase in these pathogens was seen over time. This 
demonstrated that periodontal pockets may act as reservoirs for pathogens with these 
bacteria translocating to implant surfaces over short periods of time.  
It is now widely accepted that peri-implant diseases can be considered a group of 
pathological conditions brought about by the host response to a bacterial insult in the form of 
the dental biofilm. It is this response to the dental biofilm at the implant/mucosal junction 
which results in attachment loss and destruction of the supporting tissues. As most of this 
pathology can be attributed to having a bacterial aetiology, it comes as no surprise that 
systemic antimicrobials have been considered as an adjunct to the treatment of this complex 
disease process. 
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5.4.2 The role of the microbiota and cytokines in periodontal and peri-implant diseases 
 
Page and Kornman  in 1997 detailed the pathogenesis of periodontal disease and 
emphasized that the disease process will rely on the presence and activity of certain 
pathogenic bacteria, a high local production of inflammatory mediators such as cytokines and 
low production of tissue inhibitors of inflammation.22 As an extension of periodontitis, it is 
thought that the local response to bacterial colonization around dental implants results in the 
clinical signs of peri-implant disease. 
The host response to the dental biofilm was studied by Berglundh et al using a dog model.23 
Clinical and histological analysis was conducted after plaque was allowed to accumulate 
around teeth and implants. It was found that the subepithelial connective tissue infiltrate as 
well as the composition of the cellular infiltrate was identical in the gingiva around teeth and 
the mucosa around implants. That is, the host response to de novo plaque formation was 
found to be of similar magnitude and intensity in both anatomical situations.  
In a further experimental study in dogs, Ericsson et al was able to compare the gingival 
tissues with the peri-implant mucosal tissues after 90 days of undisturbed plaque 
accumulation.24 Histology revealed that both tissues contained an inflammatory cell infiltrate 
within the apical extension of the junctional/barrier epithelium and the composition of the 
infiltrate was similar at the cellular level with significant loss of collagen observed. However, it 
was demonstrated that the inflammatory infiltrate (and therefore the host response) in the 
mucosa around implants was significantly greater than that around the gingiva. This study did 
not analyse whether this placed the implant at an increased susceptibility to bone loss but 
rather demonstrates the similarities and differences in the host response to biofilm formation 
experienced at both tooth and implant level. 
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The cause and effect relationship between plaque accumulation and development of gingivitis 
and peri-implant mucositis was demonstrated in humans.19 This study compared the clinical 
and microbiological parameters around teeth and implants after plaque was allowed to 
accumulate. The subsequent host response at the gingival and peri-implant mucosal level 
resulted in no differences in the development and progression to gingival/mucosal disease 
hence demonstrating a similar cause and effect relationship between plaque and disease. 
To analyse the pathogenesis of periodontitis and peri-implantitis, experimental ligature 
induced lesions have been studied in animal models. To study the transition of peri-implant 
mucositis to peri-implantitis and to compare this to the pathogenesis of ligature induced 
periodontitis, the ligature experimental model has been conducted in dogs and monkeys. 
Lang et al performed a ligature induced periodontitis and peri-implantitis study in monkeys 
allowing up to 8 months of plaque accumulation.25 They found that plaque and gingival 
indices, increasing probing depths and loss of attachment were identical at the ligated teeth 
and implants. They concluded that plaque accumulation generated by ligature placement 
would result in similar tissue responses at the gingival and peri-implant level. An elegant 
study by Schou et al was able to compare the host response at ligature induced disease at 
implants and at ankylosed teeth as well as normal control teeth (with a periodontal 
ligament).26 Histology demonstrated a greater inflammatory infiltrate and bone loss around 
implants and ankylosed teeth compared to control teeth. It was hypothesised that the 
absence of the periodontal ligament could promote further progression of the inflammatory 
infiltrate. 
A review paper by Birkedal Hansen et al outlined the fact that the microorganisms themselves 
and their products cannot fully explain the tissue destruction seen in periodontal diseases. 
This group explains that a combination of microbial enzymes and microbial mediators that act 
directly on host cells and the cytokine dependant host response more completely describes 
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the pathogenesis behind the tissue destruction typically seen.27 It has been proposed that 
colonization of specific pathogenic bacteria around dental implants may result in tissue 
destruction by activation of host degenerative pathways of the immune system. The review 
paper summarised the effects of these microorganisms on host tissue and how they may 
elicit tissue destruction.27 The following were highlighted: 
 Some organisms can have the ability to release proteolytic enzymes with the ability to 
degrade tissue without the intervention of host cells/response.  
 Microbial products such as leukotoxins may also trigger resident and migratory host 
cell populations to express degenerative enzymes.  
 These microorganisms may also provoke an immune response that results in the 
release of various cytokines from host immune cells that will subsequently activate 
degenerative pathways.  
 Importantly these cytokines not only target inflammatory cells such as macrophages 
but also host fibroblasts, keratinocytes, endothelial cells and possibly even 
osteoblasts. Virtually all resident cells located around the host/tooth or host/implant 
interface may be activated to have a destructive and degenerative potential. 
 
Further to this, it has been shown that certain microorganisms such as Aggregatibacter 
actinomycetemcomitans and Porphyromonas gingivalis have the ability to produce proteolytic 
enzymes with the ability to degrade collagen, a key building block to the supporting structure 
surrounding teeth and/or implants. This is however quite a simplistic view at the mechanism 
behind tissue degradation and it is likely that there are more factors at play here. 
Macrophages respond to these bacterial products including lipopolysachharide by inducing a 
range of cytokines and matrix metalloproteinases, both of which are responsible for the 
production of tissue degradative enzymes. Other microbial products such as proteinases 
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have also been shown to convert host keratinocytes and fibroblasts into highly destructive 
phenotypes thus amplifying the destructive effect of host cells themselves.28  
Over the years, there has been extensive research done looking into periodontal 
inflammatory mediators especially cytokines and their roles in tissue destruction for 
periodontal diseases. It has been shown that the host immune response plays a key role in 
the tissue destruction seen in periodontitis with cytokines such as interleukin-1β produced by 
host cells possibly involved in initiating destructive pathways resulting in osteoclastic bone 
resorption.29  
Cytokines are a group of soluble proteins that are non-specific mediators of inflammatory 
reactions which exert their immunomodulatory effects by regulating the growth, differentiation 
and transport of a wide array of host cells which when put together result in a range of 
pathological processes. Offenbacher et al sought to validate the use of a cytokine 
(Prostaglandin E2) levels within gingival crevicular fluid as a predictor of periodontal 
attachment loss. The main finding from this group was that the crevicular fluid levels of this 
cytokine had a high degree of sensitivity and specificity for predicting attachment loss.30 
 Il-1 is seen as a principal mediator of inflammation which acts on many cell types and has 
been shown to be elevated in human periodontal disease.31 Kao et al analysed the levels of 
the cytokine IL-1β in implants with peri-implantitis from samples taken from the peri-implant 
crevicular fluid. Interestingly, when IL-1β levels were compared between healthy and 
diseased implants, they were nearly four times higher around diseased implants.32 The levels 
around diseased implants were not only statistically significantly higher than in healthy 
controls, but the levels of IL-1β in these healthy sites were always consistently low. This also 
meant that the IL-1β has a high specificity as a marker for diseased implants. 
In a pilot study involving 13 patients with a total of 50 implants, peri-implant crevicular fluid 
levels were analysed for a variety of cytokines.33 Although an increase in all cytokines 
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analysed were elevated in diseased implants, the IL-1β levels were elevated by the largest 
quantities. In fact IL-1β levels were detected from sites around all implants including clinically 
determined healthy ones however the levels were statistically significantly higher adjacent to 
diseased sites by a factor of between 3-7 times. 
A further study analysed the levels of IL-1β levels in the peri-implant crevicular fluid in cases 
of health, peri-implant mucositis and peri-implantitis.34 They demonstrated IL-1β levels to be 
statistically significantly lower in cases of health compared to peri-implant mucositis and peri-
implantitis and stated that its levels were able to differentiate between the disease categories. 
It has been hypothesized and widely accepted that peri-implant disease is the result of an 
unregulated inflammatory response as a reaction to pathogenic bacteria and their products 
found within dental plaque.35 Further to this, the resultant signs and symptoms arise due to 
interactions between the bacteria, bacterial products, the biological mediators of inflammation 
and host cells with the outcome dependant on the nature and the degree of the inflammatory 
response. Studies show that the periodontitis and peri-implantitis models share common 
features, with the tissues adjacent to the tooth/implant being infiltrated by range of 
inflammatory cells such as B cells in response to plaque accumulation.36 Similar markers of 
inflammation are also upregulated in both forms of disease including a range of pro-
inflammatory cytokines such as TNF-alpha and IL-1β.37 
IL-1β is one such example of a pro-inflammatory cytokine and an important mediator of the 
host immune response to infection. In the complex events leading to cytokine release, IL-1β 
production by gingival macrophages begins at an early stage in this process.35 Although it has 
been shown to be present within the PICF around healthy implants, studies have 
demonstrated that IL-1β may be a positive predictor of the true level of inflammation at peri-
implant tissues and even resultant bone loss that occurs in peri-implantitis.35, 37, 38 Although 
these studies have indicated the potential usefulness of such biological indicators as markers 
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of peri-implant disease, further longitudinal research is required to correlate actual disease 
with these markers.  There is also a multitude of studies that have shown no correlation 
between certain biological markers and peri-implant disease.39 The majority of studies 
analysing levels of cytokines and other biological markers of inflammation with peri-implant 
disease are cross sectional in nature and this highlights the need for further prospective 
research. 
It appears that the development of peri-implantitis follows a similar pathological sequence of 
events to periodontitis however it has been shown that the rate of progression and severity of 
the inflammatory response will vary in cases of peri-implantitis. Studies have shown that 
experimentally induced plaque accumulation around dental implants in the animal and human 
models resulted in a greater degree of inflammatory cell infiltrate in the peri-implant mucosa 
compared to the gingiva around teeth,40, 41 as well as a more rapid degree of progression. In 
some cases, spontaneous progression of disease may occur whilst in others progression is 
arrested. The current thinking behind these key differences is thought to relate to the 
difference in collagen fibre arrangement and content within the tissues with a lack of fibre 
insertion seen on the osseointegrated implant. The periodontal lesion is however walled off 
by intact supra-crestal connective tissue fibres perhaps preventing the inflammatory cell 
infiltrate from directly contacting osseous tissue. 
 
5.4.3 Microbiology of healthy implants 
 
The microbiota around healthy implants has been studied and has generally been associated 
with gram positive cocci and rods with gram negative anaerobic species found in small 
numbers on occasions.42 Streptococcus mitis and Streptococcus oralis have been associated 
with early colonization of implant surfaces soon after abutment connection.20 
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5.4.4 Microbiology of peri-implant infections 
 
There is now overwhelming evidence demonstrating the association of the plaque biofilm and 
peri-implant disease. It has been shown that the contamination of implant surfaces from 
bacteria and their products is a major aetiological factor in peri-implantitis. Although complex, 
it has been shown that the microbiota within the biofilm associated with peri-implant diseases 
is similar to that found in chronic periodontitis.43, 44 In particular the “red complex” bacteria as 
termed by Socransky et al,45 as well Aggregatibacter (formally Actinobacillus) 
actinomycetemcomitans (A.a) have been found in higher proportions around diseased 
implants,46, 47 which indicates a predominance of gram negative, anaerobic species in 
diseased states. 
A recent systematic review by Mombelli et al,48 described the microbiota of peri-implant 
diseases. They concluded that the microbiological profile around diseased implants is mixed 
(both gram positive and negative), highly variable but predominated by gram negative 
anaerobic bacteria. Their review also highlighted that reports continue to show that on 
occasions the microbiological profile found in peri-implant lesions may differ to that seen in 
chronic periodontitis. Several studies have also demonstrated the presence of higher 
proportions of other microbiological species such as Fusobacterium spp, Campylobacter 
spp., Staphylococci spp. and Peptostreptococci spp..49, 50 It is worth noting that species such 
as Staphylococci spp. and Peptostreptococci spp. have historically been seen as commensal 
organisms in humans and are not normally associated with periodontal disease.  
More recently Mombelli et al reviewed the literature with regard to the microbiota associated 
with peri-implant disease.48 Data indicated that peri-implant disease may be regarded as a 
mixed anaerobic microbial infection and in most instances the subgingival flora of infected 
implants is similar in composition to the subgingival microflora associated with chronic 
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periodontitis.  They also went on to describe that such infections may also be linked to 
different microbiota such as Peptostreptococci or Staphylococci. 
In summary, the majority of the studies show the bacteria associated with health and disease 
is similar around both implants and teeth highlighting similarities between the two disease 
processes. In spite of this, there are clinical studies demonstrating high levels of other 
bacteria such as S.aureus around implants diagnosed with peri-implantitis which are not 
normally associated with periodontal disease.51 The highly variable nature of the microbiota 
reported in the literature and their key role in determining the initiation and progression of the 
disease only emphasizes the need for further research on examining the microbiological 
profile of these conditions. 
 
5.5 Diagnosis 
 
A lack of standardization in the classification of peri-implant disease has led confusion 
amongst the dental community when interpreting results from studies and clinical results. A 
systematic review by Zitzmann et al attempted to describe the prevalence of peri-implant 
disease. They highlighted the fact that several definitions of the disease exist within the 
literature.5 A study by Roos Jansaker wet al suggested that the diagnostic criteria for peri-
implant mucositis should include bleeding on probing as well as a pocket depth of 4mm or 
greater,13 while the criteria for peri-implantitis included bone loss of 1.8mm or greater 
combined with bleeding and/or suppuration when compared with one year data. A similar 
definition was also employed by Renvert et al which looked at the effectiveness of two 
different treatment modalities on implants suffering peri-implantitis.52  
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Rather than defining patients as having peri-implantitis, Fransson et al analysed the 
prevalence of subjects with implants suffering progressive bone loss over time. To meet their 
inclusion criteria, an implant must demonstrate progressive bone loss between one year after 
function and time of examination to a minimum of the third implant thread or greater.6  
Ferreira et al defined peri-implant mucositis as the presence of peri-implant bleeding on 
probing whilst peri-implantitis was defined as a pocket depth of 5mm or greater as well 
bleeding on probing and/or suppuration as well as radiographic evidence of bone loss.53 
Berglundh et al performed a systematic review on the biological and technical complications 
in implant dentistry after at least 5 years in function. This group defined peri-implantitis as an 
implant demonstrating a  probing depth of 6mm or greater in combination with bleeding on 
probing/suppuration and attachment loss/bone loss of 2.5mm.2 
The 6th European workshop on Periodontology in 2008 has more recently revised the 
definition of peri-implant diseases to as follows: 
Peri-implant mucositis is the presence of inflammation in the mucosa at an implant with no 
signs of loss of supporting bone; and peri-implantitis as in addition to the mucosal 
inflammation is characterised by the loss of supporting bone.15 
One is able to see that the variance in definitions and diagnostic criteria for these conditions 
only adds to the confusion seen by the clinician and emphasizes the lack of standardization 
that exists between clinical studies. Due to this fact, not only is the assignment of a diagnosis 
clouded but so too is the determination of disease prevalence and evaluation of treatment 
effectiveness and outcome. 
The following headings detail the commonly used parameters used to classify peri-implant 
disease. 
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5.5.1 Clinical Parameters 
 
To assess the gingiva around teeth in health and disease, a periodontal probe is most 
commonly used. It follows that the mucosa around dental implants both in health and disease 
may be also be assessed using a periodontal probe. This was demonstrated in a study by 
Lang et al whereby the histological level of periodontal probe penetration around peri-implant 
mucosa in both health and disease was analysed in the dog model.54 A correlation between 
degree of inflammation of the mucosa and increased probing depth was found, with the probe 
often penetrating beyond the barrier epithelium and into the connective tissue in cases of 
peri-implantitis. This showed that when using a light force (0.2N) probing around implants 
was a reliable method to determine loss of supporting tissue. 
Presence of bleeding on gentle probing (BOP) is often used as an indicator of mucosal 
inflammation. In the study mentioned above by Lang et al, bleeding was observed in 
approximately 67% of sites suffering peri-implant mucositis whilst 91% of implants suffering 
peri-implantitis bled on gentle probing when using a force of 0.2N. Contrary to this, healthy 
sites did not yield any bleeding on probing (0%). The results from the study demonstrate that 
absence of bleeding on probing will occur in health whilst an increasing incidence of bleeding 
on probing is likely to occur with progression of disease. 
In a study by Roos-Jansaker et al, 218 patients treated with dental implants were analysed 
for biological complications nine to fourteen years after initial therapy.55 They determined 
using uni -and multi -variate analysis that the presence of pus around the dental implant was 
correlated to a peri-implant bone level existing at 3 or more threads from the coronal aspect 
of the implant (that was defined as significant bone loss). 
Radiographic techniques to analyse bone levels adjacent to dental implants include 
orthopantamograms (OPG) or standardised intra oral radiography each with their own 
 
 
26 
                                                                         
 
limitations. Often OPGs lack image resolution and have distortion effects whilst an inability to 
determine bone levels in the bucco-lingual/palatal dimension is found with both techniques.56 
More recently the use of computer tomography or cone beam technology has offered a great 
advantage in being able to visualize osseous architecture in three dimensions. It is now 
generally agreed within the literature that radiological evidence of bone loss is a key 
fundamental criterion in the diagnosis of peri-implantitis. 
The literature indicates the aforementioned criteria critical in determining either health or 
disease of dental implants. However, there has been a growing interest in discovering new 
ways to develop tests to aid in the diagnosis of peri-implant diseases. Recently the use of 
various biological markers found in the peri-implant crevicular fluid (PICF), as well as various 
microbiological indicators to differentiate implants in a healthy or diseased state has been a 
particular area of interest. 
 
5.5.2 Peri-implant crevicular fluid (PICF) analysis 
 
Levels of various chemical mediators in the PICF have been analysed with the goal of finding 
a correlation between marker and disease. Such markers include cytokines such as IL-1 and 
proteases. The aim of this line of research is to determine if laboratory investigations could 
offer a more sensitive, reliable and more objective tool to aid in the diagnosis or even 
response to therapy. 
Kao et al assessed the levels of IL-1β within the PICF around healthy and diseased 
implants.32 Twelve patients diagnosed with peri-implantitis had IL-1β levels analysed within 
the PICF and statistically significant elevations of up to 320% were seen in the peri-implantitis 
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compared with healthy controls. They indicated that IL-1β levels could prove to be a suitable 
diagnostic marker for peri-implantitis. 
Salcetti et al assessed the levels of inflammatory and growth factor mediators as well as 
bacterial pathogens associated with failing implants compared to healthy controls.57 One 
aspect of their study involved an analysis of IL-1β levels collected from the PICF. They 
observed that IL-1β levels were found to be statistically significantly higher in cases of peri-
implantitis.  Interestingly, they also analysed a group of patients with a combination of healthy 
and diseased implants. They demonstrated that the healthy implants in this group also 
displayed statistically significantly elevated levels of IL-1β. In essence, the cytokine levels 
were elevated in the mouths which demonstrated a diseased implant, even at the remaining 
healthy sites. Such data indicates the potential role that the individual host immune response 
has at both the patient and site level towards a diseased implant, suggesting the risk of 
infection may occur at both the subject and the site/implant level. 
Conclusions from these studies may indicate the potential usefulness of such a biological 
marker to aid in the diagnosis of peri-implantitis or track response to therapy. Although other 
biological markers such as matrix metalloproteinases and prostaglandins have also been 
correlated with peri-implant disease, further well designed longitudinal studies are required to 
determine the true effectiveness and reliability of these biological indicators as a diagnostic 
tool. 
 
5.5.3 Microbiological evaluation to aid in diagnosis 
 
Luterbacher and Mayfield et al evaluated a clinical and microbiological test for monitoring 
tissue conditions during supportive periodontal therapy (SPT) and compared their diagnostic 
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characteristics at both tooth and implant sites.58 One implant and one tooth site was 
monitored for 2 years and at each recall visit both clinical analysis (particularly presence or 
absence of BOP) and microbiological samples were taken. Specifically the presence of 
bacteria Aggregatibacter actinomycetemcomitans, Prevotella intermedia, Porphyromonas 
gingivalis and Treponema denticola were examined. The diagnostic characteristics of BOP 
and microbiological tests alone and in combination were then calculated.  The results 
indicated the improved diagnostic characteristics when utilising a combination of these tests 
for implants compared to teeth were statistically significant. Importantly, they concluded that 
the addition of the microbiological test significantly improved the prognostic reliability of BOP 
alone for cases of peri-implantitis. 
Numerous studies have compared the microbiota around healthy and diseased implants with 
the main findings suggesting gram positive cocci and rods found around healthy sites whilst a 
more gram negative anaerobic flora and increased levels of spirochetes found in implants in a 
diseased state  
Leonhardt et al sought to evaluate the differences in the subgingival microbial flora in 
samples taken from sites diagnosed with peri-implantitis compared to healthy controls.46 
Samples taken from peri-implantitis cases demonstrated a flora composed of putative 
pathogens such as Aggregatibacter actinomycetemcomitans, Prevotella intermedia and 
Porphyromonas gingivalis in a majority of cases with also high numbers of Candida spp and 
Staphylococcus spp which are not normally associated with the flora found in periodontitis. 
Implants clinically diagnosed as healthy showed a flora predominately devoid of these 
pathogens. 
Salcetti et al investigated the organisms positively associated with failing implants. Plaque 
samples were taken and a DNA checkerboard analysis was conducted against 40 different 
microbial species.57 They observed organisms positively associated with peri-implantitis were 
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Prevotella nigrescens, Peptostreptococcus micros, Fusobacterium nucleatum. Interestingly, 
they concluded that some of these bacteria are in fact commensal organisms. Overall, nearly 
96% of implants that were diagnosed with peri-implantitis harboured these organisms. 
A further study sought to compare the microbial composition of the supra- and subgingival 
biofilm in subjects with and without peri-implantitis utilizing DNA checkerboard hybridisation 
techniques.59 The results of this study demonstrated higher mean counts of Porphyromonas 
gingivalis, Treponema denticola and Tannerella forsythia (red complex bacteria) as well high 
numbers of orange complex species in the peri-implantitis group, both supra- and 
subgingivally. The proportions of orange and red complex bacteria were not only elevated but 
host compatible bacteria were reduced in diseased sites compared to healthy implants. 
In summary, the microbiota associated with peri-implantitis is highly variable but typically 
associated with high counts and proportions of gram negative anaerobic species including 
members of the red and orange complex as well as Aggregatibacter actinomycetemcomitans. 
High proportions and presence of red complex species and Aggregatibacter 
actinomycetemcomitans found at implant sites may be useful supplements to improve our 
current diagnostic tools. 
 
5.6 Treatment of peri-implantitis 
 
The main goal of peri-implantitis is to control the infective process, prevent further 
progression of the disease and where possible regenerate the lost supporting tissues. 
The following tables summarise the literature with respect to studies involved in the treatment 
of peri-implantitis and has been divided with respect to non-surgical and surgical 
interventions. 
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Table 2. Non-surgical interventions in the treatment of peri-implantitis 
Author and Year Design No. of 
Subjects 
Intervention Antibiotic 
used 
Outcome 
Karring et al,
60
 
2005 
Controlled 
clinical trial in 
humans – pilot 
study 
11 patients 
with 22 
implants 
Vector System (unique ultrasonic device) 
Vs carbon fibre curettes (both non-
surgical modalities) 
No No statistical difference between two 
modalities.  
Both methods ineffective at controlling the 
inflammatory lesion. 
Khoury et al,
61
 
2001 
Controlled 
clinical trial in 
humans 
25 patients 
with 41 
implants 
Non-surgical (irrigation with CHX and 
mechanical debridement plus antibiotics) 
Vs. 
Flap surgery and autogenous graft 
(Control) 
Vs. 
Surgery plus graft plus non resorbable 
membrane (test 1) 
Vs. 
Surgery plus graft plus resorbable 
membrane (test 2) 
Yes – 
according to 
individual 
antibiotic 
susceptibility 
testing 
Non-surgical therapy was ineffective. 
Control and Test 1 performed best with 
regard to probing depth reduction, probing 
bone levels although no statistical 
significance was observed between the 
three surgical treatments affecting 
treatment outcomes at 3 years. 
Mombelli et al,
62
 
2001 
Case 
controlled 
study in 
humans 
9 patients Non-surgical mechanical therapy with 
antibiotic fibres placed subgingivally for 
10 days  
Yes – 
Tetracycline 
Fibres 
 
2/25 patients withdrawn from study at 6 
months due to persistent active peri-
implantitis. 
Significant decrease in probing depths, 
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BOP over 12 months. 
No significant change in bone levels. 
Significant decreases in anaerobic bacteria 
counts observed although gradual 
increase/rebound in counts seen over time. 
Mombelli et al,
63
 
1992 
Case 
controlled 
study in 
humans 
25 patients 
with 30 
implants 
Non-surgical debridement supplemented 
with CHX  irrigation and systemic 
antibiotic 
Yes - 
Ornidazole 
Decrease in probing depths and bleeding 
scores over one year. 
1/9 patients showed no improvement. 
Variable results in counts of subgingival 
microflora observed over 12 months. Trend 
for rebound of anaerobic bacteria observed 
over 12 months after initial reduction seen. 
Persson et al,
50
 
2011 
Randomized 
clinical trial 
21 subjects 
(test) Vs 21 
subjects 
(test) 
Er:YAG laser Vs. Air abrasive device. No PD reductions limited. No significant 
differences between groups. 
Limited reduction of certain species in both 
groups after one month. 
Both treatments failed to reduce bacterial 
counts at 6 months. 
Renvert et al 
(2009) Part I,
64
 
and Persson et al 
(2010) Part II,
65
 
Randomised 
clinical trial  
19 subjects 
(test) Vs 18 
subjects 
(test) 
Hand instrumentation (titanium curettes) 
Vs Ultrasonic device 
No 6 month results. 
Improvement in plaque and bleeding 
scores. No improvement in PPD. No 
statistical significance between treatment 
groups. 
No differences in total bacterial counts 
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found.   
Observed statistically significant increase 
in bacterial counts immediately (30 
minutes) after treatment (both groups) and 
at week one (for ultrasonic device). 
Both methods failed to reduce bacterial 
counts with no group differences observed. 
Renvert et al,
66
 
2008 
Randomised 
control trial 
16 subjects 
(test) Vs 14 
subjects 
(control) 
Non-surgical scaling and root planing 
(SRP) plus minocycline microspheres 
(test) Vs 
SRP plus CHX 1% gel (control). 
Treatments conducted at baseline, day 
30 and 90 (therefore repeated antibiotic 
use). 
Yes – 
Minocycline Vs 
CHX 
Test resulted in significant reduction in 
probing depths compared to control. 
Test group had mean probing depth 
reduction of 0.6mm at 12 months. 
NB: Average probing depth at deepest site 
did not exceed 5 mm to begin with. 
No differences in the mean total numbers 
of bacteria between or within treatment 
groups were found on the subject level or 
the implant level at any time point. 
Renvert et al,
67
 
2004 
Randomized 
controlled trial 
17 patients 
with 57 
implants 
(test) Vs 
15 subjects 
with 38 
implants 
(control) 
SRP plus minocycline (test) Vs SRP plus 
1% CHX gel. 
 
Note: patients selected with no to little 
bone loss at implants. 
Yes – 
minocycline 
microspheres 
Vs. CHX gel 
Test group resulted in improvements in 
probing depth reduction and bleeding 
scores. No effect seen in the CHX group. 
Observation period of 90 days. For deepest 
sites treated average probing depth was 
reduced from 5.0mm to 4.1mm. 
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Schwarz et al,
68
 
2006 
Clinical control 
trial in the dog 
model 
5 subjects 
with 30 
implants 
Peri-implantitis was induced by ligature 
placement in five 
Beagle dogs. 
Split mouth design. 
Closed debridement +non submerged 
healing (CNS) Vs 
Open treatment +submerged healing 
(OS) 
 
Both treatment (OS) and (CNS) groups 
were instrumented with either 
1. Er:YAG Laser (ERL) 
2. Ultrasonic (VUS) 
3. Plastic curettes and local 
metronidazole gel. 
 
Only (OS) 
group 3 – 25% 
metronidazole 
gel. 
Animals sacrificed after 3 months. 
All treatments resulted in improvements in 
clinical parameters. No significant 
differences between treatments in the CNS 
group. 
Radiographical improvements only seen in 
OS group. 
Histological analysis showed CNS group 
with very low new BIC. 
Mean BIC % for the OS group was 
statistically higher. Er:YAG (OS) showed 
the highest new BIC (44.8%). 
 
 
 
Schwarz et al,
69
 
2006 
Controlled 
clinical study 
20 patients 
with 40 
implants 
Non-surgical treatment using  
Er:YAG laser 
Vs. 
Mechanical debridement (plastic 
curettes) + 0.2% CHX pocket irrigation. 
No After 12 months no significant difference 
between the groups. 
Note that after 12 months increasing BOP 
values and loss of CAL also observed. 
Patients were therefore discontinued and 
received further surgical interventions. 
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Sahm et al,
70
 
2011 
Randomized 
controlled 
clinical trial 
15 patients 
(test) Vs. 15 
patients 
(control) 
Test group - amino acid glycine power 
(Air powered abrasive device (AAD)) Vs. 
Control - mechanical debridment with 
carbon fibre curettes and adjunct CHX 
irrigation and gel. 
No AAD showed significantly higher BOP 
reductions. 
Comparable PD reductions and CAL gain 
in both groups 
Note: PD reductions and CAL gains were 
minimal. 
Salvi et al, 
71
 2007 Case series 25 patients 
with 31 
implants 
Mechanical debridement with carbon 
fibre curettes and local CHX gel (0.1%) 
Yes – local 
delivery of 
minocycline 
microspheres 
6 implants rescued/exited from study due 
to persistent active peri-implantitis. 
Statistically significant reduction in PD and 
percentage of sites with BOP after 12 
months seen in other implants. 
Bassetti et al,
72
 
2014 
Randomized 
controlled 
clinical trial 
20 subjects 
(test) Vs 20 
subjects 
(control) 
All implants mechanically debrided with 
titanium curettes and glycine powder 
airflow system. 
Test: adjunctive photodynamic therapy 
(PDT) 
Control: adjunctive minocycline 
microspheres 
Yes – Control 
group only 
 Both methods equally effective in reducing 
BOP, PPD, microbiological counts and 
cytokine IL-1β levels. 
No statistically significant difference 
between groups after 12 months. 
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Table 3. Surgical interventions in the treatment of peri-implantitis 
Author 
and year 
Design No. of 
Subjects 
Intervention Antibiotics 
used 
Outcome 
Behneke et 
al,
73
 2000 
Controlled 
clinical trial 
in humans 
17 patients 
with 25 
implants 
Regenerative surgical 
therapy with 
autogenous bone 
Yes - 
metronidazole 
90% defect depth reduction at re-entry (3-4 months). Maintained for 3 
years. 
100% defect width reduction observed. 
Hayek et 
al,
74
 2005 
Controlled 
clinical trial 
in the dog 
model 
9 dogs 
divided into 
2 groups 
with a total 
of  18 
implants 
Access flap and CHX 
irrigation Vs. 
photodynamic therapy 
No Significant reduction of target species of bacteria in both groups. No 
significant difference between the two treatment types. 
Heitz 
Mayfield et 
al,
75
 2012 
Prospective 
cohort study 
in humans 
24 patients 
with 36 
implants 
Access flap and implant 
decontamination with 
mechanical instruments 
and sterile saline 
Yes – 
amoxycillin 
and 
metronidazole 
100% survival.  
Reductions in probing depth and BOP seen. 
92% with stable crestal bone levels or bone gain. Strict post operative 
protocols instituted. 
Romeo et 
al,
76
 2007 
Case 
controlled 
study on 
humans. 
19 patient 
with 38 
implants 
between the 
two groups 
Surgery  - 
Implantoplasty (test) Vs 
Resective surgery 
(control) 
Yes - 
Amoxycillin 
No difference in marginal bone levels (MBLs) mesial and distally after 
3 years with the test group. 
Statistical significant difference in MBLs (loss) after 3 years in the 
control group.  
Indicative that implantoplasty was an effective treatment. 
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Roos-
Jansaker 
et al,
77
 
2007 
Prospective 
Cohort Study 
17 patients 
(29 implants) 
in group 1. 
19 patients 
(36 implants) 
in group 2. 
Surgical debridement 
and surface treatment 
with hydrogen peroxide 
Group 1: Bone 
substitute and 
resorbable membrane. 
Group 2: No membrane 
Yes – 
Amoxicillin and 
Metronidazole. 
If allergy then 
clindamycin 
Equivalent probing depth reductions and defect fill. 
No significant difference between the two groups. 
 
Note: 70% of patients were smokers and high reported incidence of a 
history of periodontitis in the cohort sampled. 
Roos – 
Jansaker 
et al,
78
 
2007  
Case Series 12 patients 
with 16 
implants 
Restoration/abutment 
removed. 
Surgical debridement 
and surface treatment 
with hydrogen peroxide 
Bone substitute and 
membrane. 
Submerged healing. 
At 6 months – 
abutment reconnected. 
Yes – 
Amoxicillin and 
Metronidazole. 
If allergy then 
Clindamycin 
1 year follow up. 
Probing depth reduced by 4.2mm and mean defect fill of 2.3mm. 
Roos –
Jansaker 
et al,
79
 
2011 
Case 
controlled 
study 
15 subjects 
(27 implants) 
with bone 
substitute. 
17 subjects 
(bone 
substitute + 
Restoration/abutment 
removed. 
Surgical debridement 
and surface treatment 
with hydrogen peroxide 
Bone substitute 
material used. Half of 
Yes – 
Amoxicillin and 
metronidazole 
3 year follow up. 
No significant difference between 2 treatments i.e. membrane Vs. no 
membrane. 
 
 
37 
                                                                         
 
membrane) the patients had 
membrane whilst other 
half had no membrane. 
Abutments reconnected 
after surgery and non 
submerged healing. 
Schou et 
al,
80
 2003 
Case 
controlled 
study in 
monkeys 
8 subjects, 
with total of 
64 implants 
Experimental peri-
implantitis induced 
(TPS surface) in 
monkeys with bone 
loss between 4-6mm 
achieved. 
Surgical debridement 
and one of four surface 
preparations as follows: 
1. Air powder 
abrasive and 
citric acid 
2. Air powder 
abrasive alone 
3. Gauze soaked 
in saline and 
citric acid 
4. Gauze soaked 
in saline and 
CHX. 
Yes – 
metronidazole 
and ampicillin 
Monkey’s sacrificed after 6 months. 
Almost total bone regeneration occurred irrespective of method 
applied. A mean bone to implant contact (BIC) ratio between 39-46% 
was seen in the defects as observed histologically. 
Significant improvement in all clinical measures observed in all 
groups. Authors advocate most simple method of gauze soaked in 
saline and CHX as sufficient when combining this with their surgical 
protocol. 
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All defects filled with 
autogenous bone 
particles and ePTFE 
membrane (non 
resorbable). Non-
submerged healing. 
Membrane removal 
after 3 months. 
 
 
Schou et 
al,
81
 2003 
Case 
controlled 
study in 
monkeys 
8 subjects, 
with total of 
64 implants 
Experimental peri-
implantitis induced 
(TPS surface) in 
monkeys with bone 
loss between 4-6mm 
achieved. 
Surgical debridement 
and decontamination 
with gauze soaked in 
saline and CHX then 
one of four procedures: 
1. BioOss 
granules and 
ePTFE 
membrane 
2. BioOss only 
Yes – 
metronidazole 
and ampicillin 
Monkey’s sacrificed after 6 months. 
Clinically healthy peri-implant tissue observed irrespective of 
treatment. 
Significantly more BIC (36%) and bone gain achieved with 
combination of BioOss and membrane. 
Histology showed BioOss particles intimately integrated with 
regenerated bone. Also observed particles in occlusal portion of 
defect surrounded by connective tissue rather than bone irrespective 
of membrane use. 
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3. Membrane 
only 
4. Control (no 
further 
treatment) 
 
Non-submerged 
healing. 
Schou et 
al,
82
 2003 
Case 
controlled 
study in 
monkeys 
8 subjects, 
with total of 
64 implants 
 
Experimental peri-
implantitis induced 
(TPS surface) in 
monkeys with bone 
loss between 4-6mm 
achieved. 
Surgical debridement 
and decontamination 
with gauze soaked in 
saline and CHX then 
one of four procedures: 
1. Autogenous 
bone and 
ePTFE 
membrane (A 
+M) 
2. Autogenous 
bone only 
Yes – 
metronidazole 
and ampicillin 
Monkey’s sacrificed after 6 months. 
Significant more bone gain observed when autogenous bone used 
with or without a membrane. Significantly less bone gain observed 
with membrane only and control treatments. 
NB: Bone gain determined by subtraction radiography. 
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3. Membrane 
only. 
4. Control (no 
further 
treatment) 
Non-submerged 
healing. 
Schou et 
al,
83
 2003 
Case 
controlled 
study in 
monkeys 
8 subjects, 
with total of 
64 implants 
Experimental peri-
implantitis induced 
(TPS surface) in 
monkeys with bone 
loss between 4-6mm 
achieved. 
Surgical debridement 
and decontamination 
with gauze soaked in 
saline and CHX then 
one of four procedures: 
1. Autogenous 
bone and 
ePTFE 
membrane. 
2. Autogenous 
bone only 
3. Membrane 
only. 
4. Control (no 
Yes – 
metronidazole 
and ampicillin 
(Histologic observations) 
Monkey’s sacrificed after 6 months. 
Significant more bone gain observed when autogenous bone used 
with or without a membrane. 
Combination (A + M) produced significantly more bone gain. 45% BIC 
observed in the defects treated with A+M supported by histological 
evidence. 
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further 
treatment) 
Non-submerged 
healing. 
Schwarz et 
al,
84
 2006 
Case Series 22 patients 
with 22 
implants 
(11 per 
group) 
Surgical debridement 
and decontamination 
with sterile saline. 
Defects filled with  
Test group: 
Nanocrystalline 
hydroxyapatite (NHA) 
 
Control group: BioOss 
and BioGide membrane 
 
Non submerged 
healing 
No Both groups showed reduction in probing depths and gains of clinical 
attachment levels at 6 months post surgery. Both achieved clinically 
important improvements. However no comment on statistical 
differences between groups. 
Schwarz et 
al,
85
 2011 
Randomized 
control study 
30 subjects 
(30 implants) 
Surgical debridement 
and implantoplasty 
followed by implant 
decontamination using 
either 
1. Er:YAG laser 
2. Plastic 
No After 6 months, no significant difference between the two treatments 
with respect to BOP and CAL values (1.5 mm (laser) versus 
2.2 mm) and radiographic bone fill at the intrabony defect. 
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curettes, 
cotton pellets 
and sterile 
saline (CPS) 
Intrabony defects filled 
with BioOss and 
BioGide resorbable 
membrane. 
Non-submerged 
healing. 
 43 
  
The majority of studies in the literature report positive outcomes following adjunctive 
antimicrobial use during the treatment of peri-implantitis however there is relatively sparse 
evidence about the actual effectiveness of these antimicrobials. Of the studies that have 
analysed the results of non-surgical therapy on peri-implantitis without the use of adjunctive 
antimicrobials, the majority report minimal or unfavourable clinical and microbiological results. 
50, 60, 64, 65, 68-70 
In a consensus report at the Sixth European workshop on Periodontology it was concluded 
that because peri-implant disease is caused by bacteria, its therapy must include anti-
infective protocols.15 In accordance with this statement it was also concluded that the 
outcome of a non-surgical approach to the treatment of peri-implantitis was unpredictable 
however the use of adjunctive antimicrobials was shown to improve some clinical parameters. 
The group went on to state that the use of systemic antimicrobials in such treatment was not 
supported by enough evidence and there was a clear need to determine whether 
antimicrobials are effective in the treatment of such diseases and especially as to whether 
these initial improvements are sustained in the long term. 
A recent systematic review evaluated the therapy of peri-implantitis in a broader way, not 
restricting their analysis to randomized trials and therefore utilised a composite outcome of 
therapy. They included implant survival in the absence of peri-implant probing depths of 
≥5mm, without concomitant bleeding on probing with light pressure and no suppuration, in 
addition to no further bone loss.86 Their focus question was aimed at how successful the 
treatment of peri-implantitis is at resolution of disease. With this in mind, the review showed 
that successful treatment outcomes after 12 months of therapy could be achieved in the 
majority of patients. It was also noted that a lack of disease resolution and implant loss still 
occurred despite therapy. 
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On reviewing the literature, several protocols have been reported for the non-surgical 
treatment of peri-implantitis which involve the mechanical debridment of the implant surface 
alone or combined with antiseptics or antibiotics (Table 2). The latest review on the 
management of peri-implantitis published in 2014 noted that the analysis of efficacy of such 
protocols in controlled clinical trials is limited,87 and questioned the effectiveness of the non-
surgical management of peri-implantitis. It must be noted that their analysis did not include 
microbiological or immunological outcomes. 
In conclusion, it appears that there is a plethora of literature as to the effectiveness of 
antimicrobials in the treatment of periodontitis but whether we can extrapolate the use of 
these same drugs to the peri-implantitis model cannot be determined at this point in time. The 
literature demonstrates that local and/or systemic antibiotics are often empirically prescribed 
in conjunction with the non-surgical or surgical treatment of peri-implantitis as part of an anti-
infective protocol. It does become apparent that the available evidence to date does not allow 
any definite recommendations for the therapy of peri-implantitis and therefore only elements 
of therapy that appear to beneficial can be stated. Evidence for the use of systemic antibiotics 
in the therapy of peri-implantitis is lacking and no guidelines exist as to the type, course and 
timing of administration of these antimicrobials. There is a clear need for further well designed 
randomized control trials to be conducted in this regard.  
 
5.7 Host modulating agents 
 
As the hosts own immune system appears to plays a vital role in the progression of the 
periodontitis and peri-implantitis, the emergence of antimicrobials that have an immune 
modulating effect has become a promising approach to facilitating the treatment of the 
disease. With a greater understanding of the role that the biofilm plays in the pathological 
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process of periodontal diseases, it is generally agreed that mechanical debridement is 
essential in order to physically disrupt their habitat prior to the use of any antimicrobial 
therapy. The aim of which is to further reduce the bacterial load and enable a more effective 
healing of the wounded pocket epithelium. Whether this can be translated to the peri-
implantitis model remains to be seen. 
Tetracycline is an agent known to demonstrate anti-microbial activity but also has the ability 
to inhibit neutrophil function, collegenases and matrix metalloproteinases,88, 89 all of which 
have shown to contribute to the destruction of the periodontium. Therefore it seems logical 
that with such actions on the inflammatory/immune system, their use could have potential 
benefits in the treatment of periodontal diseases. A systematic review analysed the effect of 
one such host modulating agent (doxycycline) in the management of periodontal diseases.90 
They concluded that the use of this agent as an adjunct to mechanical therapy provided a 
statistically significant improvement in clinical outcomes compared to debridement alone. 
Macrolides are another class of drug known for their antimicrobial effects but also for their 
ability to have an immune modulating effect.  Azithromycin is a broad spectrum antibiotic 
within this family which upon administration is taken up by phagocytic cells such as 
polymorphonuclear leukocytes (PMNLs) and macrophages. This enables a unique and 
specialized way to reach sites of infection by transportation and delivery by these cells as part 
of the normal host immune response. With this ability to penetrate such cells as well as being 
able to maintain significant concentrations within the tissues, azithromycin has the unique 
ability to reach both extra and intracellular sites of infection.91-93 Azithromycin has also been 
shown to have a potent effect on neutrophil function. It has been demonstrated to not only 
inhibit the oxidative effect and chemotaxis of neutrophils but to stimulate the degranulation of 
these cells.94 As such, it may be able to dampen down a potentially overactive immune 
response by inhibiting a major source of pro-inflammatory cytokines. The drug has shown to 
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inhibit the synthesis of such cytokines in vitro but there are limited studies on its affects on 
cytokines in humans. Although, azithromycin was traditionally used by the medical profession 
for the treatment of pneumonia and urinary tract infections and more recently due to its 
immune modulating effects in the treatment of cystic fibrosis,92, 95 it has the potential 
pharmokinetic properties to significantly aid in the treatment of chronic periodontal conditions. 
There is growing evidence within the literature outlining an application for azithromycin in the 
treatment of periodontal diseases.96-99 This only highlights the need for further laboratory and 
well designed clinical research into the potential benefits of host modulating drugs such as 
azithromycin in the treatment of other inflammatory conditions such as peri-implantitis.  
 
5.8 Azithromycin 
 
5.8.1 History 
 
Antimicrobials classified as macrolides were first introduced in the 1950’s, with the use of 
erythromycin.  
The macrolide erythromycin came to fame during a pneumonia outbreak at an American 
convention centre in Philadelphia. The causative microbe was identified as Legionella 
pneumophilia which at the time failed to respond to many of the conventional antimicrobials 
used at the time. Studies soon demonstrated that patients affected by this respiratory 
infection responded more favourably following the administration of erythromycin.100 Although 
patients responded in this manner, multiple adverse side effects were experienced by 
recipients and particularly those affecting the gastrointestinal system. This was due to this 14 
ring macrolide being a potent irritant for the intestine and as a result the drug was poorly 
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tolerated.  Erythromycin was also shown to have a very limited serum concentration, a very 
narrow spectrum of antimicrobial activity and instability in gut acids.101 The need for an 
improved macrolide was required and so research was directed at an improvement in the 
chemical, microbiological and pharmodynamic properties of erythromycin. A new class of 
macrolides was born, termed azalides, in which the drug azithromycin belongs. 
 
5.8.2 Chemistry 
 
Azithromycin is structurally derived from the most commonly used form of antimicrobial within 
its family erythromycin. Azithromycin differs from erythromycin with an expansion of the 
members within its ring to 15. It also differs chemically with the addition of a methyl 
substituted nitrogen within the lactone ring creating this 15 membered structure. Such a 
modification has been shown to translate to a broader spectrum of activity against both gram 
positive and gram negative species.102 The substituted nitrogen within the glycone ring also 
makes this drug achieve a notably higher and longer sustained tissue concentration as well 
as a more prolonged half life within tissues. Importantly, azithromycin demonstrates much 
greater stability in acidic environments such as in the stomach. At 37 degrees Celsius and at 
pH 2.0, azithromycin shows degradation of approximately 10% in 20 minutes. In comparison, 
erythromycin is degraded under the same condition in approximately 4 seconds.101 As a 
result, azithromycin demonstrates approximately a 300% increase of stability in acids over pH 
ranges typically seen in the gut. This resulted in less gastrointestinal symptoms compared to 
its predecessor and also an uptake not reliant on food intake prior to consumption.103 
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Figure 1. Chemical structure of azithromycin 
The chemical structure of azithromycin demonstrating the 15 membered ring with the addition 
of a nitrogen atom resulting in the generic name of an azalide (from Williams et al,104). 
 
5.8.3 Pharmokinetics 
 
Studies have shown that following oral dosing, azithromycin is extensively distributed 
throughout the tissues within both the animal model,105, 106 and in humans.101, 107, 108 One of 
the most important features of this drug is the fact that high tissue concentrations are 
sustained despite the serum concentration dropping to very low levels. Therefore, although 
serum concentrations of the drug detected may be below the minimum inhibitory 
concentration (MIC – the lowest concentration of an antimicrobial that will inhibit the growth of 
a microorganism) for particular microbial species, often the MIC of the drug within the tissue 
is still elevated. Importantly, the clinical efficacy of the drug under such circumstances is still 
maintained.  
The high affinity of azithromycin to the tissues is thought to be due to the presence of tertiary 
amine groups which give it both hydrophilic and hydrophobic properties (what is termed 
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amphiphillic). This facilitates not only rapid tissue uptake but has been shown to sustain far 
greater tissue to serum concentration ratios of up to 100 fold,109 which is significantly higher 
than what is achieved by its predecessor erythromycin. 
 
 
Figure 2. The varying tissue concentrations of azithromycin in humans after a single 500mg 
oral dosing (from Lode et al,102). 
 
Figure 2 demonstrates the changes in concentrations of azithromycin within various tissues 
throughout the body.102 Of particular interest is the fact that 4 days after intake, despite very 
low detection rates of the drug within the serum, sustained levels of the drug were still seen in 
multiple tissues throughout the body well above the MIC for multiple pathogens. Interestingly 
it was found in tissues not normally penetrated by other antimicrobials thus suggesting the 
use of this unique drug in a manner which may be organ specific. 
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The study by Malizia et al compared the tissue distribution of azithromycin in human patients 
undergoing surgery involving third molar removal.107 They found that despite levels of the 
drug in saliva, plasma and bone levels diminished significantly seven days after drug therapy, 
the levels of azithromycin found within the gingival tissues remained elevated.   
 
Figure 3. Findings from a study investigating the concentration of azithromycin in different 
tissues in human subjects (from Malizia et al,107). Note the elevated levels of the drug 
maintained within the gingival tissues indicating a preferential localization of the drug. 
 
The preferential distribution of azithromycin demonstrated in Figure 3 suggests that this drug 
may be an effective alternative to other antimicrobials in the treatment of periodontal 
infections. Since azithromycin has also been shown to penetrate cells such as fibroblasts and 
localise itself within lysosomes, it is able to target both intra and extracellular sites of 
infection. The drug is also extensively taken up by phagocytic cells such as macrophages and 
produces significantly higher intracellular concentrations compared to the extracellular 
compartment.110 It is this lysosomotrophic behaviour which is thought to contribute to the 
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drugs preferential uptake into phagocytic cells. As a weak base, the drug demonstrates entry 
into the cells cytosome via diffusion and quickly localises itself within lysosomes by a process 
of ionization (especially at a low pH). Lysosomes fuse with phagosomes as part of the 
process of phagocytosis and this enables the drug to encounter an ingested microorganism 
uniquely and effectively. 
Gladue et al reports studies involving the release and uptake of azithromycin from human 
phagocytes.111 This group demonstrated that the intracellular to extracellular ratio was 40:1 
after only sixty minutes of intake. This ratio was found to be much greater in comparison to 
other macrolides indicating far greater intracellular levels. It is this ability to penetrate the 
intracellular compartment of cells particularly phagocytes which is essential in targeting 
facultative intracellular organisms. 
Azithromycin is thought to display excellent activity against intracellular and often persistent, 
chronic infections because of its affect towards intracellular bacteria.110 Azithromycin as a 
weak base, was shown to enter cells by both passive and active transport mechanisms,112 
and this has been thought to be due to its combination of amphophillic and lysosomotrophic 
nature. Importantly, its uptake into these phagocytic cells has no impact on the phagocytic 
capabilities or on the antimicrobial activity of the drug itself. Interestingly, the level of drug 
within the phagocytes was sustained over prolonged periods and as a result the release of 
drug at a specific site was much slower compared to erythromycin. The release of the drug 
was also enhanced in the presence of bacterial cell membranes, thus providing additional 
benefit in the presence of active infection.111 
The extent of intracellular uptake is affected by the pH, the concentration of the antibiotic, 
temperature and the activity of the cell itself. Situations where by the functional activity of the 
cell may be unregulated upon stimulation by an invading microorganism may have an impact 
directly on the extent of uptake of azithromycin into the cell. In turn, the process or stimulation 
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of phagocytosis will up regulate the accumulation of azalides into cells, especially 
phagocytes. Obviously, azithromycin concentration into phagocytes has been theorized to 
have advantages. Firstly, phagocytes may transport the drug to sites of infection and 
secondly high intracellular concentrations achieved by the drug will more effectively eradicate 
intracellular microorganisms. Importantly there is no evidence to suggest that these 
properties do not alter the phagocytic uptake in tissues, nor has it been shown to affect 
neutrophil chemotaxis or the ability of phagocytic intracellular killing. At this stage there is 
very limited evidence in the literature detailing the exact mechanism of intra-phagocyte 
activity directly on microorganisms and the aforementioned plausible advantages of these 
unique properties of the drug have only been theorized. Despite this, research into these 
unique properties of azithromycin clearly demonstrates the uptake into phagocytic cells, 
subsequently delivered to the site of infection via the hosts normal immune response and 
then released during the process of phagocytosis, delivering a high and targeted 
concentration of the drug locally. An example of this targeted delivery system was shown in a 
study which demonstrated high concentrations of azithromycin in alveolar macrophages and 
leukocytes after short term oral administration.113 
Gladue and Snider et al showed that fibroblasts and phagocytes concentrate azithromycin 
and these cells may act as a reservoir providing not only a source of the drug for intracellular 
uptake but also to maintain levels of the drug extracellularly.114 This is possibly an important 
mechanism for the drug’s efficacy against an invading pathogen by maintaining adequate 
concentrations both intra and extracellularly.  
Research has demonstrated that azithromycin is delivered via two mechanisms. Tissue 
uptake occurs directly and then also uniquely by phagocytic cells to deliver the drug locally 
and specifically to sites of infection. As a result of these unique drug properties, we need to 
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realize that serum concentrations of the drug do not reflect the bioavailability of the drug in 
tissue. 
 
5.8.4 Metabolism 
 
The primary method of azithromycin metabolism is via hepatic demethylation, a process 
resulting in breakdown of the chemical structure of the drug with the aid of enzymes. 
Importantly, the metabolites of this process are thought to display no antimicrobial activity,106 
and the majority of the absorbed dose is not metabolized. In humans approximately 5% of the 
drug is eliminated in urine unchanged and without distribution. A further 20% of the drug upon 
reaching the systemic circulation is excreted via this route also and it has been shown that 
the faecal route is an important means for excretion of the drug. Serum elimination of the 
drug occurs rapidly and was shown to be due to its rapid uptake into tissues, where it is 
distributed and finally eliminated. A study demonstrated that after the initial decline in serum 
concentrations following administration of azithromycin, small peaks were seen over an 
observed period within the serum itself.115 This was deemed to be due to the slow release of 
the drug from tissues over a prolonged period. 
 
5.8.5 Dosing 
 
There are two typical dosing regimens for azithromycin and both involve administration of 
1500mg over 3 to 5 days. The first regime involves one 500mg tablet per day for three days. 
The second involves a 500mg tablet taken on day one, followed by one 250mg tablets taken 
each day for four days. 
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Due to the drugs sustained half life, both regimes have been shown to be effective at 
achieving maximal MICs toward targeted microbiological species over an extended period of 
time. As azithromycin also displays a preferential uptake into lung tissues, its use in 
respiratory medicine is well documented. In a randomized study determining the effect of a 
three or five day course of the drug in patients with atypical pneumonia, both regimes were 
found to be equally as effective in its treatment effect.116  
 
5.8.6 Side Effects 
 
A recent retrospective analysis published in the New England Journal of Medicine found a 
small but definite increase risk of patients prescribed a 5 day course of Azithromycin with 
sudden cardiac death.117 This serious side effect was found to be most pronounced in 
patients at a high risk of cardiovascular disease which they defined by a cardiovascular risk 
score. This score was based on factors such as prior myocardial infarction, diabetes, age and 
gender. This group went on to hypothesize that azithromycin may have a proarrhythmic 
affect. Further well designed clinical trials must be conducted in order to validate this finding. 
However, in the meantime, precaution is warranted when prescribing azithromycin in patients 
demonstrating high cardiovascular risk factors. 
There have been reports of the risk of sensorineural hearing loss with the use of azithromycin 
in prolonged courses.118 Such instances may occur in the treatment of chronic infections for 
example mycobacterium lung infections. There have also been reports of this serious adverse 
event occurring in patients treated for acute otitis media even at low doses.118 As a result, 
clinicians should be aware of the incidences of these serious adverse events occurring in 
some patients.  
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Reported side effects of azithromycin include headaches, gastrointestinal disturbances, 
nausea and vomiting,119 all of which have been experienced with the intake of other 
antimicrobials. The most frequently reported adverse events were analysed in a recent meta- 
analysis which compared the relative risks ratios of these adverse events occurring between 
patients administered azithromycin and those given a placebo.120 The events analysed were 
a cough, headache, abdominal pain, vomiting, nausea and diarrhoea and found no statistical 
significant relationship between these adverse events and the consumption of this 
antimicrobial versus a placebo. Mortality rates were not discussed as it was not reported 
within the literature that they analysed. A further report described the incidence of adverse 
effects occurring in children at approximately 9%. However, these events were often mild to 
moderate in nature which rarely required the need to cease the drug regime.121 
 
5.8.7 Microbiological effects 
 
Erythromycin, a macrolide was first introduced in the 1950’s and was shown to have a similar 
activity to benzylpenicillin. However, it differed in that it also displayed activity against 
anaerobic bacteria including those that displayed resistance to benzylpenicillin. It displayed 
effectiveness against Mycoplasma pneumonia and other bacteria normally resistant to beta-
lactam antibiotics. This unique spectrum of activity prompted the search for newer variations 
of this class of drug with fewer side effects and drug interactions. Effectively a new class of 
drug was developed termed azalides of which azithromycin belongs and is structurally 
derived from the macrolide family of drugs. 
Macrolides are bacteriostatic agents that reversibly bind to the 23S ribosomal RNA of the 50S 
subunit of the bacterial ribosome thereby inhibiting ribosomal protein synthesis.122  
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The microbiological activity of azithromycin can be classified under the following headings as 
described by Williams et al:123 
Activity against rapidly growing pyogenic bacteria: 
 Azithromycin has been shown to display effectiveness against strains of staphylococci  
spp. that are resistant to penicillin and methicillin. Streptococci are more susceptible to 
macrolides than staphylococci and resistant strains are rarely seen.123 
 As well as showing efficacy against Enterococcus spp, importantly azithromycin has 
displayed its effectiveness toward Neisseria gonnorrhoeae,101, 123 one of the major 
causes of sexually transmitted infections. 
Activity against bacteria resistant to benzylpenicillin and erythromycin: 
 Enterobacteria spp. and Pseudomonas spp. commonly display resistance to 
erythromycin and benzylpenicillin whereas azithromycin has been shown to be 
effective against both these organisms. 
 Azithromycin is effective against strains of Haemophilus influenza, the bacteria 
responsible for multiple opportunistic respiratory infections such as pneumonia and 
bacterial meningitis. Erythromycin only displays limited effectiveness against this 
bacterium. 
Activity against organisms susceptible to erythromycin and tetracycline: 
 Azithromycin consistently displays heightened levels of activity against Chlamydia spp 
and Helicobacter pylori compared with erythromycin and tetracycline which indicates a  
role for azithromycin against opportunistic infections in immunocompromised 
patients.124 
 Azithromycin has also been demonstrated to have a broad spectrum of antimicrobial 
effects with activity against not only pyogenic bacteria such as Staphylococci spp. but 
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also bacteria resistant to penicillin and erythromycin. It has been shown to be more 
effective than either of these two agents in many cases. 
 
Although azithromycin was traditionally used by the medical profession for the treatment of 
pneumonia and urinary tract infections and more recently due to its immune modulating 
effects in the treatment of cystic fibrosis,92, 95 it has the potential pharmokinetic properties to 
significantly aid in the treatment of other chronic inflammatory conditions. Macrolide 
antibiotics have demonstrated an ability to inhibit biofilm formation via several proposed 
mechanisms including inhibiting bacterial gene products responsible for biofilm formation or 
inhibition of bacterial products necessary for the biofilm scaffold.125 In an in vitro model, 
azithromycin was shown to be highly effective in killing Porphyromonas gingivalis infected 
biofilms,126 and has been reported to suppress critical virulence factors required by the biofilm 
for quorum sensing.127, 128 Azithromycin has also been shown to be highly effective at 
inhibiting growth of a variety of strains of gram negative bacilli and anaerobic bacteria.129 
 Macrolide antimicrobials have also demonstrated an ability to interfere with other bacterial 
virulence factors such as bacterial adhesion capacity, bacterial motility and bacterial toxins.125 
Specifically, azithromycin has shown to inhibit a host of bacterial toxins and virulence factors 
such as elastase, protease and DNase.130 
 
5.8.8 Antimicrobial resistance 
 
Over the past few years it has become evident that there has been an increase in the 
incidence of bacterial resistance to macrolide antimicrobials. This resistance is achieved by 
one of two mechanisms, either by altering the binding site for macrolides on the ribosome or 
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by active efflux.125 The efflux mechanism occurs via specific macrolide efflux genes which up 
regulate proton pumps thereby facilitating clearance of the drug whilst specific ribosome 
methylation genes mediate the inability of the drug to bind to 23S ribosomal RNA.131 
Pneumococcal resistance to macrolides has reported to be prevalent with surveillance 
studies conducted in the United States revealing between 28-34% of S. Pneumonia are 
macrolide resistant.131 
 
5.8.9 Host modulating effects 
 
Azithromycin has also been shown to have a potent effect on neutrophil function. It has 
demonstrated not only to inhibit the oxidative effect and chemotaxis of neutrophils but to 
stimulate the degranulation of these cells.132 This study measured the levels of azithromycin 
in blood plasma and also within the neutrophils themselves over several weeks. They found 
that the plasma levels of the drug had significantly decreased after 24 hours and was 
undetectable after 28 days. However, levels of the drug found in neutrophils were maintained 
at a high level after 24 hours and still detectable after 28 days. This finding would have a 
profound influence on the ability of this drug to exert not only its antimicrobial effect but also 
its anti-inflammatory/immuno-modulatory effect over an extended period of time. Alternatively, 
it has been described that azithromycin can upregulate macrophage chemotaxis and 
phagocytosis thus potentially enhancing its antimicrobial effect by stimulation of the hosts 
own immune defences against invading microorganisms. As well as this, azithromycin has 
shown to have a pro-apoptotic affect toward inflammatory cells and this may have 
implications as a means to resolve chronic inflammation.125 
 59 
  
The drug has also shown to inhibit the synthesis of pro-inflammatory cytokines such as 
interleukin 1, 6 and tumour necrosis factor alpha both in vitro and in studies on its affects on 
cytokines in humans.94 
Azithromycin has also demonstrated an inhibitory effect on adhesion molecule expression 
and chemotaxis thus affecting the fundamental process of leukocyte adhesion and movement 
to sites of inflammation. By disturbing this key process of the inflammatory cascade, 
azithromycin can exert a potent anti-inflammatory effect. This has significant implications on 
the use of the drug in chronic inflammatory conditions including that found in the respiratory 
system and oral cavity. Azithromycin differs from other macrolides due to its ability to 
accumulate rapidly in cells and tissues and also due to a comparatively long half life enabling 
a slower release from these sites.122 As a result of this long half life, dosages (500mg taken 
once over three days) are kept comparatively low compared to other antimicrobials and this 
has obvious implications on patient compliance. 
 
5.8.10 Influence on cytokines 
 
Cytokines consist of a family of biological regulators that are produced by most cells of the 
body. The importance of these proteins cannot be underestimated due to their effects on 
surrounding cells, which in turn will affect the outcome of the response to a particular 
infection. The production of the appropriate type of cytokines will be essential for producing a 
protective immune response and conversely an aberrant production of inappropriate 
cytokines may result in destructive and progressive disease. The balance in production of 
these cytokines will therefore be paramount to an effective immune system. 
 60 
  
Macrolides inhibit the synthesis of pro-inflammatory cytokines and also regulate the release 
of anti-inflammatory cytokines. 
Bartold and co-workers have summarised the effects of azithromycin on cytokines.125 The 
following table will summarise the effects of azithromycin on the cytokine IL-1β which is a 
topic of focus of this study on both human tissue/cells and in the animal model. 
 
Table 4.  The effects of azithromycin on the cytokine IL-1β 
Author Source Regulatory 
effect 
Cai et al 2013.133 Bronchoalveolar macrophages in humans. Suppressed 
Hao et al 2013.134 Murine plasma. Suppressed 
Srivastava et al 
2012.135 
Chlamydial elementary bodies from cervical 
swabs in humans. 
Suppressed 
Ivetic et al 2012.136 Ear tissue biopsy – murine model. Suppressed 
Srivastava et al 
2011.137 
Cytobrush samples from cervix in humans. Suppressed 
Marjanovic et al 
2011.138 
Sputum samples in humans. Suppressed 
Tong et al 2011.139 Myeloid cells - murine model. Suppressed 
Ho et al 2010.140 Human gingival crevicular fluid (GCF). Suppressed  
Li et al 2010.141 Human corneal epithelial cells. Suppressed 
Meyer et al 2009.142 Alveolar macrophages in mice affected by 
cystic fibrosis. 
Suppressed 
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Tsai et al 2009.143 Cystic fibrosis mice infected with 
P.aeruginosa. 
Suppressed 
Beigelman et al 
2009.144 
Mouse model of allergic inflammation. No effect 
Bosnar et al 2009.145 Murine lung macrophages. Suppressed 
Geudens et al 2008.146 Supernatant of bronchial lavage of mice. Suppressed 
Reato et al 2004.147 Human polymorphonuclear neutrophils 
taken from peripheral venous blood. 
Suppressed 
Culic et al 2002.132 Human neutrophils in serum. Increased after 
24 hours and 
return to baseline 
at 28 days 
 
The majority of studies in the literature demonstrate a suppressive effect of azithromycin 
toward the pro-inflammatory cytokine IL-1β with the minority showing no effect and one study 
demonstrating an up regulating effect on human neutrophils.132 Further studies are clearly 
needed in analysing the effect that azithromycin has on IL-1β in other chronic inflammatory 
conditions such as periodontal diseases. 
 
5.8.11 Use in periodontal and peri-implant therapy 
 
The following is a summary of the literature on the effects of azithromycin toward various 
periodontal/implant conditions. It is worth highlighting that only one of the studies in table 5 
relates to peri-implant conditions. The impact on components that may have an effect on the 
treatment outcome such as microbiological and immunological parameters is highlighted. 
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Table 5. A summary of the literature on the effects of azithromycin toward various 
periodontal/implant conditions. 
Author Aim Summary of findings 
Lai et al 2013.148 Compare levels of 
azithromycin in the gingival 
crevicular fluid (GCF) Vs blood 
serum at 2, 4, and 7 days 
Mean GCF levels were 
significantly higher in GCF 
throughout the test and above 
minimum inhibitory concentrations 
for various periodontal pathogens 
Gannon et al 
2013.149 
Effect of azithromycin on 
human osteoclast formation 
and resorptive activity. In vitro 
model. 
Reduction of resorptive activity 
observed with significant reduction 
in osteoclastic formation when 
higher concentrations tested.  
Han et al 2012.150 Efficacy of azithromycin as an 
adjunct to non-surgical therapy 
in patients with chronic 
periodontitis. 
Significant reduction in clinical and 
microbiologic parameters as well 
as cytokine tested however no 
difference seen between placebo 
group. 
No additional benefit seen. 
Haas et al 
2012.151 
Compare microbiological 
outcomes of azithromycin and 
placebo as adjunct to 
supragingival scaling in 
aggressive periodontitis cases. 
Azithromycin produced no 
adjunctive benefit in reducing 
subgingival periodontal pathogens 
in combination with supragingival 
scaling. 
Haas et al 
2012.152 
Compare microbiological 
outcomes of azithromycin and 
placebo as adjunct to 
supragingival scaling in 
aggressive periodontitis cases. 
Significant radiographic bone level 
changes seen however no 
difference between groups. 
Azithromycin had no additional 
benefit. 
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Emingil et al 
2012.153 
Effectiveness of azithromycin 
compared to placebo as 
adjunct to non-surgical therapy 
in aggressive periodontitis 
cases. 
Azithromycin produced no 
additional benefit. 
Hallstrom et al 
2012.154 
Compare non-surgical therapy 
of peri-implant mucositis with 
and without azithromycin 
antibiotic. 
No additional clinical and 
microbiological benefit seen. 
Tyaji et al 
2011.155 
Compare clinical effects of 
scaling and root planing (SRP) 
with and without azithromycin 
gel in chronic periodontitis 
cases. 
The adjunct use of azithromycin 
demonstrated statistically 
significant improved results 
compared to SRP alone. 
Sampaio et al 
2011.156 
Compare the effects of 
azithromycin as an adjunct to 
SRP in chronic periodontitis 
cases. 
No adjunctive benefit in clinical 
and microbiological outcomes 
observed. 
Schmidt et al 
2011.157 
Monitor effects of azithromycin 
as an adjunct to SRP in 
chronic periodontitis cases 
Improvement in clinical results 
maintained for 192 weeks 
Hirsch et al 
2010.158 
Cases reports of the effect of 
azithromycin in chronic 
periodontitis cases 
Improved clinical and radiographic 
parameters observed 
Oteo et al 
2010.159 
Compare the effects of 
azithromycin as an adjunct to 
SRP in chronic periodontitis 
cases. 
Significant improvement with the 
adjunct use of azithromycin in 
clinical and microbiological 
parameters compared to placebo. 
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Yashima et al 
2009.160 
Compare full mouth and partial 
mouth SRP (conducted within 
7 days) using azithromycin 
with conventional SRP (~ 1 
week between sessions) 
without antimicrobials. 
Improved clinical and 
microbiological results using 
antimicrobial.  
Pradeep et al 
2008.161 
Compare the effects of 
azithromycin as an adjunct to 
SRP in chronic periodontitis 
cases. 
Improved clinical and 
microbiological parameters seen 
in azithromycin group. 
Haffajee et al 
2008.162 
Compare azithromycin, 
metronidazole and doxycycline 
as adjunct to SRP Vs SRP 
alone. 
Significant reduction in bacterial 
complexes seen in groups using 
azithromycin or metronidazole as 
well as sustained clinical 
improvements. 
Haas et al 
2008.163 
Compare the effects of 
azithromycin as an adjunct to 
SRP in aggressive 
periodontitis cases. 
Azithromycin group showed 
greater probing depth reduction 
and clinical attachment level gain 
compared to placebo control. 
Dastoor et al 
2007.164 
Compare the effects of 
azithromycin as an adjunct to 
periodontal surgery in smokers 
with chronic periodontitis. 
Adjunct use of azithromycin 
showed no benefit in 
improvements of clinical 
parameters. 
A greater sustained reduction in 
periodontal pathogens was seen 
in the azithromycin group 
compared to placebo. 
Schmidt et al 
2007.165 
Case reports of the effect of 
azithromycin as an adjunct to 
Radiographic evidence of bone 
formation seen after therapy 
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periodontal therapy 
Ramalho et al 
2007.166 
Effect of azithromycin and oral 
hygiene (OH) measures Vs 
OH alone in patients with 
cyclosporine induced gingival 
hyperplasia 
Azithromycin group had a 
significant reduction in gingival 
hyperplasia and plaque scores 
compared to oral hygiene 
measures alone 
Gomi et al 
2007.99 
Compare full mouth SRP with 
azithromycin (test) Vs 
conventional SRP. 
Greater improvements in clinical 
parameters with FM-SRP plus 
azithromycin. 
Target bacterial recolonization 
occurred in both groups but 
delayed in the test group. 
Mascarehas et al 
2005.98 
Compare the effects of 
azithromycin as an adjunct to 
SRP in smokers with chronic 
periodontitis. 
Azithromycin group showed 
greater reductions in probing 
depths and clinical attachment 
level gains as well as an 
enhanced microbial response. 
Smith et al 
2002.97 
Effectiveness of azithromycin 
compared to placebo as 
adjunct to non-surgical therapy 
in chronic periodontitis cases. 
Azithromycin group resulted in 
greater pocket depth reduction. No 
difference seen in plaque, 
bleeding and calculus indices. 
Herrera et al 
2000.167 
Effects of azithromycin Vs. 
amoxicillin/clavulanate in 
treatment of periodontal 
abscesses (with mechanical 
therapy instituted 10-12 days 
after antibiotic). 
Both regimes effective in 
treatment of periodontal 
abscesses. 
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When reviewing the literature, there are limited well designed studies analysing the effect of 
azithromycin in the treatment of periodontal conditions. In vitro studies looking at the effect of 
azithromycin on specific target cells of the periodontium such as osteoclasts are encouraging. 
A detailed in vitro analysis of the effect of azithromycin on human osteoclast formation by 
Gannon and co workers highlights this point.149 
The evidence summarised in table 5 illustrates the outcomes of the adjunctive use of 
azithromycin in periodontal therapy are variable with the majority of data showing more 
favourable clinical, microbiological and immunological outcomes. However there is recent 
published data showing no or little benefit on outcomes tested with the adjunctive use of 
azithromycin toward periodontal conditions.156, 164 Interestingly, only one study analysed the 
impact of azithromycin at the implant level and this was in cases of peri-implant mucositis.154 
Whether the potential benefit of adjunctive use of azithromycin in the treatment of periodontal 
conditions can be applied to the peri-implantitis model remains to be seen and further well 
designed trials are required in order to investigate this matter further. 
 
5.8.12 Concluding remarks on azithromycin 
 
Azithromycin is a broad spectrum antimicrobial derived from the macrolide family termed 
azalides. An important feature of this drug is that it has an ability to obtain high tissue 
concentrations and displays effective delivery to the site of infection. It differs from other 
macrolides due to its ability to accumulate rapidly in cells particularly fibroblasts and tissues 
and also due to having a comparatively long half life enabling a slower release from these 
sites. With this in mind, it has been shown to be effective against common and also not so 
common infections often resistant to other antimicrobials. 
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From a pharmacological perspective, it displays very different kinetics in all regards especially 
pertaining to the dosing regimens, making it far more amenable to patient compliance. 
Despite some of the earlier macrolides showing significant drug interactions with multiple 
medications and also undesirable side effects, the literature tends to favour the use of 
azithromycin as being far better tolerated whilst still maintaining its efficacy over a broad 
range of infections. 
 
6.0 Conclusion 
 
Peri-implantitis can be considered a pathological condition brought about by the host 
response to bacterial insult in the form of the dental biofilm. It is hypothesised that it is this 
host response to the dental biofilm at the implant/mucosal junction which results in 
attachment loss and destruction of the supporting tissues seen. There is evidence to suggest 
that in cases of peri-implantitis, the submucosal flora is predominated by anaerobic species 
with higher proportions of red and orange complexes observed. We therefore sought to 
determine the frequency of detection of specific bacteria complexes found at the peri-implant 
interface in cases of peri-implantitis 
Literature reports a significant number of patients with implants are affected by this condition 
and as such will continue to become a burden to the patient and practitioner. Although there 
are recommendations which guide our therapy of the disease, there is no conclusive 
evidence to show which of these is the most effective. To the best of our knowledge there are 
no randomized controlled trials analysing the use of systemic antimicrobials in the non-
surgical treatment of peri-implantitis. 
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Because of the association of bacteria to the condition, antimicrobials should be considered 
as a therapy potentially suitable to the treatment of peri-implantitis. The unique properties of 
azithromycin, as discussed in this review, lend itself to the therapy of chronic inflammatory 
conditions such as that seen in peri-implantitis. Despite this, there is little evidence to date of 
the use of azithromycin in the treatment of this condition and this warrants further 
investigation. The literature has shown a significant correlation between cytokine levels and 
periodontal attachment loss with statistically significant elevation of IL-1β levels at disease 
active sites compared with controls. More recently, there is data to suggest that IL-1β may be 
a convenient marker for peri-implant health and disease. In this study, IL-1β was used as a 
general marker of inflammation around implants diagnosed with peri-implantitis and we 
sought to determine possible host modulating effects following azithromycin dosing. 
Significant tissue substantivity of azithromycin has also been reported and therefore the 
detection of this antimicrobial within the PICF samples was monitored throughout various 
time points.  
In addition to its host modulating properties, azithromycin has been demonstrated to be a 
broad spectrum antimicrobial and its effect on the levels of anaerobic and aerobic 
microbiological counts was specifically undertaken in this study. 
Upon reviewing the literature it becomes clear that the need for further research into the 
benefits of the use of azithromycin in the therapy of peri-implantitis is warranted in view of its 
unique pharmokinetic properties. 
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7.0 Aims 
 
The aim of this study is to determine in a randomized trial the treatment effect of azithromycin 
(AZM) versus a placebo at the peri-implant tissue level in a group of patients diagnosed with 
peri-implantitis. 
Specifically, the primary aims are to: 
1.  Quantify the microbiological levels of anaerobic and aerobic bacteria present in the 
peri-implant crevicular fluid (PICF) around implants diagnosed with peri-implantitis 
before, during and after treatment within the 2 groups. 
 
2. We also aim to quantify a pro-inflammatory mediator, IL-1β known to initiate 
periodontal tissue breakdown in the diseased state throughout the course of 
treatment. 
Secondary aims are: 
1. To determine the range species of bacteria residing at the implant interface and 
grouped according to microbial complexes.  
2. Monitor the presence of Azithromycin in the peri-implant cervical fluid (PICF) 
throughout the course of the study. 
3. To determine the frequency of “positive responders” to treatment. This was defined as 
the percentage frequency of patients who displayed a decrease in microbiological and 
immunological parameters from baseline. 
Our objective is to elucidate the biological effect of azithromycin in cases of peri-implantitis. In 
using a human disease model, we seek to compare the effect of non-surgical therapy with or 
without the adjunctive use of azithromycin. 
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7.1 Objectives of Null Hypothesis 
 
The null hypothesis states that 500mg of azithromycin given for three consecutive days offers 
statistically significant microbiological and immunological benefits when compared with 
placebo in the non-surgical management of peri-implantitis. 
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8.0 Materials and methods 
 
8.1 Trial Design 
This pilot study was part of a double blinded randomised control trial evaluating the clinical 
and microbiological outcomes and levels of IL-1β following the non-surgical debridement with 
or without adjunctive azithromycin in subjects diagnosed with peri-implantitis. This part of the 
study reports on the microbiological outcomes and IL-1β levels. 
The study was designed as a double blinded, prospective randomised placebo controlled 
clinical trial for a period of 6 months. Ethical approval was obtained from the Western Sydney 
Local Health District Human Ethics Committee; approval reference number HREC2012/11/4. 
6(3569) AU RED HREC/12/WMEAD/273. A detailed participant information sheet was 
provided to the volunteers and a written consent form was signed by each participant. Refer 
to appendix for patient information and consent form. 
Notification to conduct a clinical trial involving drugs under the Clinical Trial Notification (CTN) 
scheme, pursuant to Schedule 5A of Regulation 12 of the Therapeutics Goods Regulation 
was lodged and approved by the Therapeutics Goods Administration (Australian 
Government) under trial number 2013/0330. 
 
8.2 Participants and Settings 
 
Patients referred to the Westmead Centre for Oral Health (Westmead, Sydney Australia) for 
the management of peri-implantitis were assessed for eligibility for participation in this study. 
Subjects were included on the following criteria: 
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8.3 Eligibility criteria of participants 
Inclusion criteria of participants included the following: 
1. Age >18 years 
2. Absence of uncontrolled systemic disease 
3. Peri-implantitis defined as: 
a. Pocket probing depth of  ≥5 mm with bleeding on probing with or without 
suppuration  
b. Radiographic bone loss of >2 mm after abutment connection  
4. Presence  of one or more single implant accessible to peri-implant probing 
Exclusion criteria were as follows:  
1. Any uncontrolled medical diseases 
2. Smoking defined as >5 cigarettes/day 
3. Untreated periodontal disease 
4. Plaque index above 25% 
5. Use of antibiotics in the past 6 months 
6. History of allergy to azithromycin or other macrolide antibiotics 
7. Patients with known cardiac arrhythmias  
8. Pregnant and lactating women 
9. Implants inaccessible to peri-implant probing  
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8.4 Outcome variables 
 
We aimed to monitor changes in microbiological counts, changes in levels of the cytokine IL-
1β and in levels of azithromycin from samples taken from the peri-implant crevicular fluid 
(PICF) at various time points before and after mechanical therapy. 
The primary outcome variables were changes in anaerobic and aerobic microbiological 
counts expressed as colony forming units per ml (CFU/ml) as well as changes in the 
immunological parameter IL- 1β from samples taken from the PICF (expressed as pg/ml). 
Secondary outcome variables include the detection of azithromycin found in the PICF over 
time (expressed as a positive or negative result) and to account for the variety of species of 
bacteria associated with peri-implantitis (as frequency detection of bacterial complexes). 
We also aimed to determine the frequency of “positive responders” to treatment. This was 
determined by the percentage frequency of patients who displayed a decrease in 
microbiological and immunological parameters from baseline. 
 
8.5 Randomisation  
 
Subjects were randomised to receive adjunctive azithromycin or a matched placebo 
according to a computer generated table (Excel 2010 Microsoft® software). The table was 
generated by a person blinded to the treatment allocation. 
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8.6 Protocol 
 
Subjects who fulfilled our eligibility criteria were invited to participate in the study and 
informed written consent was taken. 
After oral examination including full mouth plaque scores with plaque disclosing solution at six 
sites per tooth or implant, probing depths, attachment levels, bleeding index and standardized 
periapical radiographic analysis of the affected implant(s) was undertaken as described in 
part I of this study. 
All subjects had at least one implant diagnosed with peri-implantitis (see definition in section 
6.3). In cases where multiple implants were present in the same subject, the worst affected 
implant was selected for study. The remaining affected implants were also treated but their 
data was not included in the analysis of the study. 
It was a requirement of that any existing periodontitis found in the subjects must be treated 
prior to progression in the study. 
The treatment protocol was provided by one operator (LG) who remained blinded to the 
allocation of the treatment group. The drug (or placebo) was issued in a concealed container 
labelled with subject number only and issued by the Clinical Trials Pharmacist at the 
University Clinic Pharmacy (Westmead Hospital, Westmead NSW Australia). 
At baseline, participants were given appropriate oral hygiene advice which consisted of tooth 
brushing technique of the entire mouth with focus on the affected implant as well as 
interproximal cleaning techniques with the use of interdental brushes (TePe 
Munhygienprodukter AB, Malmö Sweden). 
Mechanical treatment was only performed at baseline (Day 1) and subjects in both groups 
received mechanical debridment using titanium curettes (LM instruments, Ergomix, Parainen 
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Finland) and polishing with rubber cups and prophylaxis paste (Ainsworth Prophy Paste, 
Ainsworth Dental, Marrickville NSW Australia). Local anaesthetic with lignocaine with 
adrenaline (2% XYLOCAINE® Dental with Adrenaline 1:80,000 Dentsply (Australia) Pty Ltd) 
was used in all cases. 
Following mechanical treatment, subjects were issued the drug or placebo by the University 
Clinic Pharmacy under direction of the Clinical Trials Pharmacist according to the 
randomization envelope with assignment code. The subjects and examiner were blind to the 
assignment of drug/placebo. Subjects were issued one of the following in a concealed 
container: 
Azithromycin 500mg dosing consisted of 1 capsule per day for 3 days (3 capsules in total) or 
Placebo (1 capsule per day for 3 days). All capsules were prepared by a compounding 
pharmacist (Stenlake Compounding Chemist, Bondi Junction, NSW Australia) with identical 
appearance. 
Subjects returned at days 3, 7, 21, 90 and 180 for follow up microbiological and 
immunological sampling. Compliance was checked by a phone call (Day 2) following non-
surgical treatment and by all patients returning the empty bottles on day 3. Any adverse 
effects were also recorded on patient record sheet.  
Any patients showing signs of deterioration including increasing bleeding, suppuration, pain 
or discomfort were to be withdrawn from the study and offered surgical peri-implant 
treatment.  
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8.6.1 Sample Collection 
 
The designated implant diagnosed with peri-implantitis was isolated with cotton rolls, any 
supra-mucosal plaque was removed with sterile cotton pellets followed by the placement of 
one sterile endodontic paper point (ISO 055, DENTSPLY Mailleffer, Montigny Le Bretonneux, 
France) into the peri-implant sulcus and held in place for 20 seconds. Two samples were 
taken at each site for microbiological and immunological testing (i.e. one each) by one 
examiner blinded to the treatment protocol (AK). Care was taken not to contaminate the 
samples with saliva. 
Microbiological samples were then transferred to sterile vials and immediately collected by a 
laboratory assistant for processing on site at the Identification Reference laboratory, Centre 
for Infectious Diseases and Microbiology Laboratory Services (CIDMLS) at the Institute for 
Clinical Pathology and Medical Research (ICPMR) at Westmead Hospital, NSW Australia. 
Microbiological sampling was conducted at baseline (day 1) and repeated at days 3, 7, 21, 90 
and 180. The site with the deepest probing depth was used per implant for sampling and 
remained as the designated sampling site for the subject throughout the study. It should be 
noted that the baseline sampling was carried out prior to initial subgingival mechanical 
therapy (outlined below). 
Collection of samples for the immunological analysis was conducted using the exact protocol 
mentioned above and transferred into a 1.0ml sterile microcentrifuge tube (Eppendorf South 
Pacific Pty. Ltd. North Ryde NSW 2113 Australia) containing 1ml Dulecco’s phosphate buffer 
saline (PBS) (Walkersville, MD U.S.A.). Samples were stored at -80 degrees Celsius within 
15 minutes of sampling until assayed. 
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8.6.2 Microbiological analysis 
 
The total viable aerobic and anaerobic microbiological counts expressed as colony forming 
units per ml (CFU/ml) were obtained by culturing methods (refer to section 8.6.2.2). The 
primary aim of the microbiological analysis was to determine the means of these counts and 
compare between the two treatment groups. Further analysis of this data is conducted to 
elucidate changes in counts from baseline levels. 
Secondarily, we aimed to account for the variety of species of bacteria associated at the peri-
implant interface and analyse them according to microbial complexes as outlined by 
Socransky.45 The bacteria analysed and their corresponding complexes to which they belong 
can be found in Appendix table a. If one member of a complex was observed, then this was 
tallied for that respective complex. 
The frequency of detection of these complexes was then analysed at baseline and 
comparisons between treatment groups made. This was done as a convenient way to profile 
the microorganisms at the peri-implant interface with emphasis on known pathogenic species. 
The processing was carried out by experienced microbiological/laboratory staff not directly 
involved with the study and therefore blinded to the treatment allocation. The processing 
occurred within 15 minutes of receiving samples from the authors and conducted at the 
CIDMLS. Their process is described below: 
 
8.6.2.1 Sample preparation 
 
The paper points were placed in 200µl of nuclease free water in a sterile microcentrifuge tube 
(Eppendorf South Pacific Pty. Ltd. North Ryde NSW 2113 Australia) and vortexed for 1 
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minute to create a dilution of 2.0 x 10-2. Further serial dilutions were conducted by diluting the 
remaining sample 10 fold each time (10µl in 90µl of Schaedler’s broth which is a general 
purpose medium for the cultivation of aerobic and anaerobic bacteria) up to 2.0 x 10-4. Culture 
of each dilution was conducted with a 10µl sample or aliquot added to each plate used. 
 
8.6.2.2 Culture 
 
Anaerobic culture: 
Samples were inoculated onto selective and non selective plates containing the following 
media: 
 Horse blood agar (HBA) 
 Brain Heart Infusion (BHI) agar with added haemin and vitamin K (BHV) 
 BHV + muramic acid 
 Aggregatibacter actinomycetemcomitans selective medium (AASM) 
For culture and identification of Aggregatibacter actinomycetemcomitans, a selective media 
was prepared according to the method of Tsuzukibashi et al.168  
 Anaerobic agar plates were incubated anaerobically in specialized jars (GENbox, anaer, 
Biomerieux®, Lyon France) using  the AnaeroPack system (see Delaney et al,169) at 37 
degrees Celsius for 7 days and left undisturbed. 
Aerobic culture: 
Samples were inoculated onto non selective plates containing the following media: 
 Chocolate agar 
 HBA 
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Aerobic plates were incubated in an atmosphere of 5% CO2 to facilitate growth of aerobic 
species at 37 degrees Celsius for 5 days undisturbed. 
 
8.6.2.3 Microbiological Counts and Identification 
 
After incubation, total colony counts (TCC) were calculated and proportions of aerobic and 
anaerobic bacteria relative to TCC were conducted. Detection limits were set at 2 x 104 
CFU/ml. This was conducted by the examiner (AK) whom remained blinded to the treatment 
allocation at this stage and under the supervision of the staff at CIDMLS. 
Initial identification of aerobic and anaerobic species was conducted with the use of Matrix 
Assisted Laser Desorption Ionization Time-Of-Flight (Maldi-Tof) processor (see Carbonnelle 
et al,170 for review). Matrix-assisted laser desorption/ionization (MALDI) is an ionization 
technique used in the mass spectrometry based analysis of biomolecules such as proteins. 
Maldi-Tof utilizes the intrinsic property of mass spectrometry to detect the mass to- charge 
ratio of a bioanalyte and is therefore able to provide a unique mass spectral fingerprint of a 
microorganism. 
Bacterial identification is based on the fact that the spectral fingerprints picked up by the 
machine vary between microorganisms and the molecular masses detected are specific to 
genus, species and even subspecies. The Bruker Daltonics MALDI Biotyper™ is a 
commercially available automated microbial identification system which uses this technology 
to identify organisms based on their protein profiles and used in this study. Maldi-Tof has 
been engineered with a large database of reference strains of bacteria of which the analysed 
sample can be compared to, after which the species detected are printed out within minutes 
for analysis. The protein spectra were compared to the Bruker ™ Biotyper MALDI-TOF 
database (version 3.1).  
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Several specific periodontal pathogens were not contained within the Maldi-Tof database and 
therefore standard microbiological culture techniques were employed by experienced 
technicians as follows: 
Tannerella forsythia was cultured with a selective medium using n-acetyl muramic acid. 
Colony appearance after 7 days resembled small grey-white colonies (0.5-1.0mm in 
diameter) and under the stereomicroscope appeared moist and shiny with white internal 
flecking. Standard microbiological testing confirmed these as gram negative fusiform rods 
that were indole negative. 
Porphyromonas gingivalis was identified as a black pigmented species with the following 
biochemical reactions: trypsin positive, indole positive, catalase positive or negative and 
displayed sensitivity to vancomycin (5µg disc). Occasional strains were found to be 
vancomycin resistant but confirmed as Porphyromonas gingivalis by 16S rRNA gene 
sequencing. 
Prevotella spp were identified with the following reactions: indole positive or negative, trypsin 
negative, catalase positive and displayed resistance to vancomycin 5µg 
If the above microbiological techniques were unable to identify a particular species, a 
Polymerase Chain Reaction (PCR) analysis utilising 16S rRNA gene sequencing was 
performed as outlined in Relman et al.171 This is a single amplification PCR incorporating 
three separate reactions. Broad range primers are used to amplify regions within the 16S 
rRNA gene. The 16S rRNA gene provides a unique signature of most bacteria and the 
identification can then be determined by a sequence analysis of the amplified products. 
This technique conducted by staff at CIDMLS is outlined in brief below: 
DNA was extracted using the NucliSens™ easyMAG (bioMerieux Australia Pty Ltd.) 
automated system and was performed according to the manufacturer’s instructions. 
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Three separate PCR master mixes were prepared, each incorporating a respective set of 
primers which recognize different conserved sequences within the 16S rRNA gene. 10L of 
DNA extract was assayed in each reaction. Examination of PCR amplicons was performed by 
agarose gel electrophoresis which was then analysed by DNA sequencing using an external 
automated DNA sequencer at the Australian Genomic Research Foundation (AGRF). 
Analysed sequences received from AGRF for each mastermix reaction are assembled to 
produce a larger sequence prior to performing nucleotide blast (basic local alignment search 
tool) analysis against the National Center for Biotechnology Information (NCBI) nucleotide 
database collection. Queries with 99% identification were considered correct to the species 
level. 
 
8.6.3 Concentration of azithromycin 
 
The processing was carried out by trained microbiological staff not directly involved with the 
study and therefore blinded to the treatment allocation. Note that sample collection and 
processing occurred within 15 minutes from sample collection. The process was carried as 
described by Driscoll et al,172 and is summarised below: 
Preparation of plates inoculated with the indicator organism Bacillus subtilis, known to be 
susceptible to azithromycin were prepared as follows: 
A sample of Bacillus subtilis (taken from a stock broth) was transferred to a 2.5ml solution of 
sterile saline to create a 0.5 McFarland suspension (this is a reference used as a standard to 
adjust the turbidity of bacterial suspensions). 
This suspension was streaked over the surface of a Mueller-Hinton agar plate (100mm in 
diameter) with a sterile swab to create a lawn culture of Bacillus subtilis and allowed to 
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incubate overnight at 37°C. Care was taken to ensure the agar layer on each plate was of an 
even thickness. 
Sample preparation: 
50µl of the sample was taken from the primary diluent (i.e. after the paper points were placed 
in 200µl of nuclease free water in a sterile microcentrifuge tube and vortexed for 1 minute to 
create a dilution of 2.0 x 10-2) and were stored in an identical Eppendorf tube at -70°C for 
batch testing. 
24 hours prior to batch testing the samples were defrosted and then 10 µl of this fluid was 
drawn up in a pipette and inoculated directly onto sterile paper discs and placed onto the 
prepared agar plates. 
Plates were allowed to incubate overnight at 37°C and read 24 hours later. Specimens with 
sufficient concentration of antimicrobial to cause of bacterial zone of inhibition were noted as 
a positive result. Zones of inhibition are considered to give a relative concentration of the 
antimicrobial therefore only a semi quantitative analysis was conducted. 
 
8.6.4 Cytokine Assay 
 
The enzyme linked immunosorbent assay (ELISA) for IL-1β was conducted at the Centre for 
Immunology and Allergy Research, Westmead Millennium Institute by examiner (AK) under 
the supervision of the senior laboratory manager. 
The pro-inflammatory cytokine IL-1β concentrations in the PICF samples were assessed 
using a commercially available ELISA (eBioscience® San Diego, CA USA) Human IL-1β 
ELISA Ready Set Go! ® kit. The procedure is described below. 
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The capture antibody provided in the kit is made up of mouse anti-human IL-1β. This was 
diluted to 2 g/ml with phosphate buffer solution TE (PBS).  100 litres was immediately 
added to the required wells of a 96 well plate and plates were covered with an adhesive cover 
and incubated at 4C overnight. 
The following day (24 hours later), contents of the well were removed and washed three 
times with PBS (350 litres per  well per wash) after which 300 litres of blocking solution, 
provided in the kit (3% Bovine Serum Albumin (BSA) + PBS) was added and then incubated 
at room temperature for 2 hours. The contents of each well were removed followed by the 
addition of 100 litres of the IL-1β standard (recombinant human IL-1β found in the kit). 
Plates were then incubated at room temperature for a further 2 hours after which contents of 
the wells were again removed and washed five times with the washing solution provided in 
the kit (PBS with 0.05% Tween 20 (PBS-T)). 
100 litres of biotin-conjugated detection antibody made up of biotin-conjugated goat anti-
human Immunoglobulin as part of the kit (diluted 1 in 100 with reagent diluent) was then 
added and the plates were incubated for 2 hours at room temperature. 
Well contents were removed and washed again (five times) with the washing solution. 
100 litres of streptavidin- horseradish peroxidase (HRP) conjugate (found in kit) was then 
added (diluted 1 in 1000 with reagent diluent) and incubated at room temperature for 30 
minutes. The contents were again removed and washed five times with the washing solution. 
 100 litres of tetramethylbenzidine (TMB) solution from the kit was added to each well and 
incubated at room temperature protected from light for 20 minutes. 50 litres of stop solution 
was then added. 
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The contents were then read in a plate reader using spectrophotometry (Perkin Elmer 2030 
Multi label reader Victor ™ X3, Massachusetts U.S.A.) at 450 nm and adjusted values 
obtained by subtracting measurements at 570 nm to account for background scatter. 
Results were then prepared and analysed utilising a standard curve created from software 
program Prism™ 6 (GraphPad Software Inc. San Diego CA U.S.A). 
 
8.7 Statistical analysis 
 
Descriptive statistics and statistical analysis were performed with the statistical package IBM 
SPSS Ver. 21 (USA). Variables were presented as absolute values and relative frequencies 
(%). The statistical computational unit was taken at the subject level. 
Baseline characteristics of age (independent samples t-test), gender and subjects with a 
history of periodontitis (Mann-Whitney U test) were analysed to determine if treatments 
groups were statistically significant from one another. Results were regarded as statistically 
significant at p <0.05. 
Only one implant per subject was included in the study, therefore data was analysed on a 
subject level. 
Chi-Squared tests were applied to determine if the frequency detection of the various 
microbial complexes were statistically significant between treatment groups at baseline. 
Results were regarded as statistically significant at p <0.05. 
Microbiological and immunological counts taken per subject were pooled to a mean value. 
The independent samples t-test was applied to this data to determine if mean counts per 
treatment group were statistically different from one another at the 6 different time points. 
This was also applied to determine if the changes in the mean counts from baseline between 
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the two treatment groups were statistically different from one another.  Results were regarded 
as statistically significant at p <0.05. 
An analysis of the effect of time (across the length of the study and between the individual 
time points) on the microbiological and immunological outcome measures across all patients 
and within each treatment group was performed. This was conducted using a repeated 
measures ANOVA and pairwise comparisons using Bonferroni corrections. Significance was 
found if p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
  
 86 
  
9.0 Results 
 
9.1 Subject information 
 
Twenty-five consecutive patients referred to the Westmead Centre for Oral Health 
periodontics department for the management of peri-implantitis were recruited into the study. 
Eight of these patients did not fit all the inclusion criteria therefore seventeen subjects were 
accepted for the study. The mean ages for the test and control groups were 59.7 (SD = 13.1) 
and 64.4 (SD = 8.5) respectively with no significant differences between groups (p=0.400). 
There were 9 subjects in the test (4 males and 5 females) and 8 subjects in the control (3 
males and 5 females) with no significant differences between treatment groups for gender 
(p=0.780). There were 8 subjects with a history of periodontitis in our subject cohort. There 
was no statistical significant difference between the two groups for those with a history of 
periodontitis at baseline (p=0.470). 
One hundred percent compliance was obtained by all subjects with the return of empty 
capsule containers on day 3. No patient was withdrawn from the study due to persistent 
symptoms or deterioration of their implant condition. One patient was lost to follow up at day 
180 due to relocation and the data for that time point was not included in the analysis. 
 
9.2 Adverse events 
 
Two patients in the azithromycin group reported an adverse event which was stomach 
cramping and diarrhoea and one of these patients reported transient chest pain one day after 
administration of treatment. This patient recovered uneventfully. Both patients recovered 
uneventfully and did not report lasting side effects. 
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9.3 Microbiological analysis   
 
Figure 4 demonstrates an example of bacterial species cultured at different dilutions with 
horse blood agar (HBA) in anaerobic conditions (a) 2.0 x 10-2, (b) 2.0 x 10 
-3, (c) 2.0 x 10 -4. 
Bacterial counts were conducted from such plates and expressed as anaerobic and aerobic 
counts.  
 
Figure 4. Anaerobic plates demonstrating cultured species at different dilutions. 
 
(a)                                                                                (b) 
             
          (c) 
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Table 6 shows the patient mean and standard deviations for aerobic bacteria at 6 time points 
between the two treatment groups calculated from Appendix tables b and c. No significant 
differences were observed between the treatment groups at any of the times points. 
 
Table 6. Mean aerobic count (CFU/ml x106) (Azithromycin versus Placebo groups) 
Day  Azithromycin Placebo p value 
1 77.904 (SD=130.450) 94.964 (SD=166.486) 0.816 
3 46.764 (SD=132.507) 66.743 (SD=96.060) 0.73 
7 26.459 (SD=40.601) 23.555 (SD=34.141) 0.876 
21 32.939 (SD=64.017) 74.966 (SD=125.144) 0.389 
90 16.73 (SD=21.658) 114.075 (SD=166.654) 0.144 
180 138.060 (SD=349.111) 89.101 (SD=164.305) 0.725 
* Significant difference p<0.05 
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Figure 5 shows the mean aerobic counts between the two treatment groups over the 6 
individual time points calculated from table 6. Counts are expressed as CFU/ml (x106). Both 
treatment groups showed a trend for the mean aerobic bacterial count to decrease from day 1 
to 7. The reduction in the levels of aerobes continued through to day 90 in the azithromycin 
group before increasing to above baseline levels. In contrast, the placebo group showed a 
trend for aerobic bacteria to steadily increase and rebound after day 7. This rebound 
appeared to be delayed until day 90 in the azithromycin group. No statistical significant 
differences between the two treatment groups were observed at any times points. 
 
Figure 5. Mean aerobic counts (Azithromycin Vs Placebo) 
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Table 7 shows the patient mean and standard deviations for anaerobic bacteria at 6 time 
points between the two treatment groups calculated from Appendix tables d and e. 
Differences between groups approached significance at day 90 in favour for the azithromycin 
group however no significant differences were observed between the treatment groups at any 
of the times points observed. 
 
Table 7. Mean anaerobic count (CFU x106) (Azithromycin Vs. Placebo groups) 
Day  Azithromycin Placebo p value 
1 225.056 (SD=243.87) 262.093 (SD=392.675) 0.816 
3 56.501 (SD=142.941) 235.205 (SD=347.942) 0.177 
7 62.294 (SD=92.896) 76.666 (SD=141.871) 0.806 
21 92.776 (SD=163.887) 373.346 (SD=492.78) 0.127 
90 60.067 (SD=90.715) 377.335 (SD=390.064) 0.056 
180 168.621 (SD=303.543) 296.495 (SD=437.186) 0.508 
*Significant difference p<0.05 
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Figure 6 shows the mean anaerobic counts between the two groups (azithromycin and 
placebo) over the 6 individual time points calculated from table 7. Counts are expressed as 
CFU/ml (x106). Both treatment groups showed a trend for the mean anaerobic bacteria count 
to decrease from day 1 to 7 after which a gradual increase in counts was observed for the 
remainder of the study. The magnitude of this rebound in anaerobic bacteria levels was 
greater in the placebo group. There were no statistical significant differences observed 
between the two groups at any times points. 
 
Figure 6. Mean anaerobic counts (Azithromycin Vs Placebo) 
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Table 8 shows the mean change in aerobic bacteria from baseline between the two treatment 
groups calculated from Appendix tables f and g expressed as CFU/ml x 106. No significant 
differences were observed between groups at any time point. 
 
Table 8. Mean Change from baseline in aerobic bacteria (Azithromycin Vs. Placebo) 
Day  Azithromycin Placebo p value 
3 -31.141 (SD=162.560) -28.221(SD=196.540) 0.974 
7 -51.446 (SD=133.964) -71.409 (SD=152.552) 0.778 
21 -44.965 (SD=155.299) -19.998 (SD=186.955) 0.768 
90 -61.174 (SD=133.872) 19.111 (SD=259.324) 0.427 
180 100.417 (SD=358.373) -5.863 (SD=268.889) 0.513 
*Significant difference p<0.05 
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Figure 7 shows the mean change in aerobic total viable count from baseline expressed as 
CFU/ml x 106 calculated from table 8. The zero on the y-axis represents baseline/pre 
treatment level at day 1. The placebo group showed a mean change resulting in a reduction 
of aerobic bacteria levels up to day 7. After day 7, there was a gradual increase in aerobic 
bacteria levels towards baseline. The azithromycin group showed a mean change resulting in 
reduction of aerobic bacteria levels up to day 90 with an increase above baseline levels 
observed at day 180. There were no statistical significant differences observed between the 
two treatment groups across the time points. 
 
Figure 7. Mean changes from baseline in aerobic bacteria counts (Azithromycin Vs. 
Placebo)  
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Table 9 shows the mean change in anaerobic bacteria from baseline between the two 
treatment groups calculated from Appendix tables h and i expressed as CFU/ml x 106. No 
significant differences were observed between groups at any time point. 
 
Table 9. Mean Change from baseline in anaerobic bacteria (Azithromycin Vs. Placebo) 
Day  
 
Azithromycin 
 
Placebo 
 
p value* 
 
3 -168.554 (SD=244.690) -26.888 (SD =540.142) 0.488 
7 -162.761 (SD=224.603) -185.426 (SD=407.716) 0.887 
21 -132.280 (SD=230.550) 111.254 (SD=628.897) 0.295 
90 -164.989 (SD=296.884) 115.243 (SD=588.626) 0.226 
180 -9.566 (SD=411.532) 34.403 (SD=695.572) 0.880 
*Significant difference p<0.05 
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Figure 8 shows the mean change in anaerobic total viable count from baseline expressed as 
CFU/ml (x106) calculated from table 9. The zero on the y-axis represents baseline/pre 
treatment levels at day 1.  The placebo group showed a mean change resulting in reduction 
in anaerobic bacteria counts up to day 7, after which a rebound in bacteria levels were 
observed above baseline levels and sustained throughout the remainder of the study. The 
azithromycin group showed mean changes resulting in a sustained decrease in mean 
anaerobic bacteria levels below baseline observed up 180 days.  
 
Figure 8. Mean change in anaerobic bacteria counts from baseline 
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Table 10 shows the percentage frequency of viable bacterial complexes found by culture at 
baseline (pre treatment). If at least one species from a complex was detected, this was 
tabulated accordingly. 
Across all subjects and between groups, the orange complex species were found in the 
highest frequency (94.1%). Bacteria of the purple, green and yellow complexes were also 
found at varying frequencies whilst the red complex bacteria were found at the lowest 
frequency (17.6%). 
There were no significant differences between treatment groups observed at baseline.  
The species of bacteria analysed and their respective complexes can be found in the 
Appendix table a. 
 
Table 10. Frequency of viable bacterial complexes observed in subjects at baseline 
(expressed as a percentage) 
Complex All subjects Azithromycin group Placebo group p value* 
Purple 58.8 55.6 62.5 0.772 
Green 35.3 55.6 12.5 0.064 
Orange 94.1 88.9 100 0.331 
Yellow 58.8 44.4 75 0.201 
Red 17.6 11.1 25 0.453 
*Chi-Squared test P<0.05 shows significant difference 
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Figure 9 illustrates the percentage frequency of bacteria complexes found at baseline for (a) 
all subjects and (b) between treatments groups (A- azithromycin; P-Placebo). The proportions 
of bacterial complexes between treatment groups was similar (no significance differences 
found) at baseline. 
 
Figure 9. Frequency of viable bacterial complexes observed at baseline (expressed as 
a percentage) 
9 (a). 
  
  
0 
20 
40 
60 
80 
100 
Purple Green Orange Yellow Red 
% 
Bacterial Complex 
 Frequency of microbial complexes at 
baseline  
(all subjects) 
 98 
  
9 (b). 
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Figure 10 illustrates the percentage frequency of positive responders between the two 
treatment groups for (a) aerobic and (b) anaerobic bacteria counts. Data calculated from 
Appendix tables f, g, h and i. It was observed that the frequency of subjects who were 
“positive responders” was consistently higher in the azithromycin group for both aerobic 
(exception at day 7) and anaerobic counts. 
A “positive responder” was a subject who demonstrated a decrease in bacterial counts from 
baseline levels. 
 
Figure 10. The frequency of positive responders for aerobic counts. 
10 (a). 
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10 (b). 
  
 
Analysis of microbiological counts across time  
An analysis of the microbiological data was conducted to determine significant differences 
across time within each treatment group.  
For the anaerobic count, no statistical significant differences was found for the effect of time 
across all patients (p=0.412). Equivalent findings were observed for the anaerobic change 
scores (p=0.246) and within each treatment group for azithromycin (p=0.548) and placebo (p 
=0.437). Pairwise comparison showed no statistical significant effect of time within each 
treatment group (p>0.05). 
For the aerobic count, no statistical differences was found for the effect of time across all 
patients (p=0.558). Equivalent findings were observed for the aerobic change scores across 
all patients (p=0.471) and within each treatment group for azithromycin (p=0.504) and 
placebo (p= 0.645). Pairwise comparison showed no statistical significant effect of time within 
each treatment group (p>0.05). 
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9.4 Concentration of azithromycin 
 
After the plates were incubated for 24 hours at 37°C, specimens with a bacterial zone of 
inhibition were noted as a positive result. No positive results (zones of inhibition) were 
observed in the samples across any of the time points. These samples equated to a 1/20 
dilution factor from the original sample. 
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9.5 Cytokine IL-1β analysis 
 
Figure 11 demonstrates the IL-1β plate after set up and prior to reading by the 
spectrophotometer. The first 3 wells on the far left show the standards prepared from 5 to 500 
pg/ml of which a standard curve was created. 
 
Figure 11. IL-1β plate in spectrophotometer. 
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Figure 12 shows the standard curve created for IL-1β at concentrations ranging from 7.5-
500pg/ml. An optical density (OD) reading was obtained using spectrophotometry after which 
a concentration could be obtained from the standard. 
 
Figure 12. Standard curve created for IL-1β  
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Table 11 demonstrates the mean and standard deviations for IL-1β levels between the two 
treatment groups calculated from Appendix tables j and k expressed as pg/ml. No statistical 
significant differences were observed between treatment groups at any of the time points 
observed. 
 
Table 11. Mean IL-1β levels (Azithromycin vs. Placebo). 
Day  Azithromycin Placebo p value 
1 114.348 (SD=160.291) 85.919 (SD=77.072) 0.655 
3 34.172 (SD=30.138) 33.135 (SD=23.695) 0.939 
7 25.125 (SD=17.816) 46.662 (SD=38.005) 0.174 
21 23.821 (SD=25.511) 45.757 (SD=32.441) 0.14 
90 21.396 (SD=19.74) 36.059 (SD=28.614) 0.233 
180 21.242 (SD=15.132) 51.456 (SD=43.548) 0.098 
*Significant difference p<0.05 
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Figure 13 shows the mean levels (expressed as pg/ml) of IL-1β between the two treatment 
groups over time calculated from table 11. Both groups demonstrated a trend for mean 
reduction in IL-1β levels after treatment over time which was sustained throughout the study. 
No statistical significant difference was observed between treatment groups. 
 
Figure 13. Mean IL-1β levels (Azithromycin vs. Placebo) 
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Table 13 shows the mean change in IL-1β levels from baseline between the two treatment 
groups calculated from Appendix tables l and m expressed as pg/ml. No statistical significant 
differences were observed between groups at any time point. 
 
Table 13. Mean changes in IL-1β levels (Azithromycin vs. Placebo). 
Day Azithromycin Placebo p value 
3 -80.176 (SD=168.006) -52.784 (SD=83.269) 0.683 
7 -89.223 (SD=157.158) -39.257 (SD=88.244) 0.440 
21 -90.527 (SD=136.219) -40.162 (SD=88.191) 0.387 
90 -92.952 (SD=141.770) -49.860 (SD=81.640) 0.462 
180 -44.572 (SD=78.319) -34.463 (SD=48.157) 0.760 
*Significant difference p<0.05 
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Figure 14 demonstrates the mean changes in IL-1β levels from baseline expressed as pg/ml 
calculated from table 13. Both groups demonstrate a decrease in IL-1β levels after treatment 
and showed a trend for an increase or rebound in these levels over time. The magnitude of 
change appeared greater in the azithromycin group. No statistical significant differences were 
observed between treatment groups at any time point.  
 
Figure 14. Mean IL-1β level changes from baseline (Azithromycin vs. Placebo) 
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Figure 15 illustrates the percentage frequency of positive responders between the two 
treatment groups for IL-1β levels. Data calculated from Appendix tables l and m. 
A “positive responder” was a subject who demonstrated a reduction in IL-1β levels from 
baseline. It was observed that the percentage frequency of subjects who were positive 
responders was consistently higher in the azithromycin group at all time points. 
 
Figure 15. The frequency of positive responders for IL-1β levels 
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statistical significant effect of time within each treatment group (p>0.05). No statistical 
differences were observed for the IL-1β change from baseline scores (p=0.720). 
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10.0 Discussion 
 
10.1 Subjects 
 
The patient sample represents a group of older public health patients in an Australian 
population diagnosed with peri-implantitis.  There were no statistical differences between 
treatment groups for age and gender. Treatment groups were also analysed at baseline for 
bacterial counts, proportions of bacterial complexes observed and IL-1β levels.  Although no 
statistical significant differences were observed, we cannot assume that subjects in both 
treatment groups had an equivocal experience of inflammation and microbial pathogenic load 
due to low subject numbers. 
 
This study relied on the referral of patients from private practices mainly from internal 
departments within the hospital. Despite extensive advertising and promotional efforts made 
to the dental profession in New South Wales, Australia, we were unable to attract referral 
from private practices. There may be many reasons for this,  including a lack of desire to refer 
to what is largely a post graduate training facility or inadequate amount of information 
regarding the study design and hence hesitation in referral. Despite this, further studies 
should take this into account and allow greater time to build a subject base. A larger cohort of 
study subjects would likely improve the chance of achieving statistically significance 
differences between treatment groups. 
To the best of our knowledge, this is the first study conducted which attempted to test the 
hypothesis that Azithromycin (500mg) given for three consecutive days offers improved 
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microbiological and immunological benefits when compared with a placebo in the non-
surgical management of peri-implantitis. 
 
10.2 Microbiology 
 
The findings of this study show a trend for a greater and prolonged decrease in aerobic and 
anaerobic bacteria counts with those subjects dosed with azithromycin. This is reflected in the 
mean counts and the mean changes in these counts from baseline levels. This study also 
demonstrated that the frequency of subjects who were considered “positive responders” were 
consistently greater in the azithromycin group. 
In the literature reviewed, there are several protocols and methodologies for the treatment of 
peri-implantitis such as mechanical debridement, the use of antiseptics and antimicrobials, 
use of lasers and photodynamic therapy as well as surgical interventions with or without 
regenerative procedures. A recent systematic review concluded that there is very little 
evidence to suggest which treatment method is most effective for peri-implantitis due to a lack 
of well designed randomized control trials.173  
There are reports in the literature which analyse the microbiological effects of adjunctive 
therapies on peri-implantitis but no study to date has attempted to analyse the effect of 
azithromycin in cases of peri-implantitis. In 1992, Mombelli et al sought to determine the 
effectiveness of adjunctive antimicrobial treatment on peri-implant infections.63 Mechanical 
treatment was supplemented with adjunctive systemic ornidazole (1000mg for 10 days). 
Statistical significant reductions in total bacteria count were observed immediately after 
therapy. However, these changes were not sustained for a long period with a gradual 
increase in counts and species observed over time with a peak in reoccurrence of several 
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organisms after 3 months. Anaerobic counts returned to baseline levels after 6 months. Our 
study showed a similar antimicrobial effect in which mechanical therapy with adjunctive 
azithromycin (500mg/day for 3 days) demonstrated a reduction in anaerobic viable count from 
baseline levels over a period of 6 months. Rebound was similarly observed and was 
approaching baseline levels by 6 months.  
In a separate study, Mombelli et al investigated the microbiological effects of the local 
delivery of tetracycline in peri-implantitis.62 Mechanical therapy was supplemented with 
adjunctive tetracycline fibres and left in situ for 10 days with absence of a control intervention. 
They demonstrated a sustained decrease in mean total viable count and mean gram negative 
anaerobic rods for up to 6 months after therapy. However there was a trend for a rebound of 
these counts over time.  
Another study by Persson et al assessed the microbiological outcomes of adjunctive local 
minocycline microspheres in cases with peri-implantitis using DNA-DNA checkerboard 
hybridisation and a follow up of 12 months.174 They observed a reduction in all bacterial 
complexes analysed up to day 60 after which a gradual rebound was observed. Although 
similar trends were observed in our study, one must be cautious in extrapolating these results 
with our study due to the relative differences between systemic and local antimicrobial 
therapy. 
A study by Renvert et al evaluated the clinical and microbiological outcomes of repeated 
administration of local minocycline in cases of peri-implantitis,66 compared to topical 
chlorhexidine gel (CHX) as control. All cases received non-surgical debridement (scaling and 
root planing) plus either adjunctive minocycline or CHX gel which was randomly assigned. 
Treatment was repeated at days 30 and 90. Interestingly, despite a statistically significant and 
sustained reduction in probing depths after 6 months compared to the control (CHX) group, 
no differences in the mean total numbers of bacteria between or within treatment groups were 
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found at the subject or implant level. This is in agreement with our findings of a trend for a 
decrease in microbial counts in the short term but no statistical significant difference observed 
between treatment groups at any time point. 
Our study is in general agreement with existing literature in that we found a highly variable 
peri-implant microflora predominated by gram negative anaerobic species. The study showed 
that although a trend for a more sustained decrease in aerobic and anaerobic bacteria was 
observed in subjects who were given azithromycin as an adjunctive therapy, no statistical 
difference was seen between treatment groups. Rebound in the aerobic and anaerobic 
bacteria count was seen over time, although appeared to be delayed in the azithromycin 
group likely corresponding to a recolonization of bacteria at the peri-implant interface.  The 
high variability in bacterial counts encountered between individual patients in placebo and 
azithromycin groups made it difficult to analyse the data with the small sample sizes we 
obtained. The sample sizes were 9 patients in the azithromycin group and 8 patients in the 
placebo group. This is certainly a limitation of the study and perhaps an extended recruitment 
process could have been undertaken. The microbiological data collected was not only large in 
scale but also highly variable which resulted in large standard deviations. This may also 
account for the lack of statistical significance between groups observed which may be 
improved with a larger subject population. Future studies should take this into account when 
trying to determine statistical significance between two treatment groups.  
Because of the high degree of variability in bacterial counts between patients, we decided to 
perform an analysis of the mean changes from baseline between the two groups. We found 
this an effective method to monitor the changes that may be observed between groups over 
time as it determines the variations in bacterial counts compared to pre treatment/baseline 
levels. The decrease in bacterial count (aerobic and anaerobic) observed in both treatment 
groups after 7 days may be expected as a result of a ‘Hawthorne effect’ whereby the subjects 
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improved their oral hygiene practices over the initial period since they were seen at more 
frequent intervals. However this cannot account for the sustained reductions below baseline 
levels observed in the azithromycin group when these recall periods were extended out. In 
spite of this, by 6 months there was no statistical significance differences observed when 
comparing the changes in bacteria counts from baseline between test and control groups. 
An analysis was also conducted to determine the effect of time on microbiological counts. 
This was conducted in order to evaluate if time rather than the actual treatment affected the 
outcome. No statistical significant effect of time was observed within each treatment group for 
microbiological counts. 
The results of this study demonstrate the highly variable nature of the bacterial flora 
associated with peri-implantitis. It has been shown that the microbiota within the biofilm 
associated with peri-implant diseases to be similar to that found in chronic periodontitis.43, 44  
In a landmark study, Socransky et al described certain microbial complexes in subgingival 
plaque around teeth.45 They were able to demonstrate the presence and levels of 40 
subgingival species after which community ordination was performed. They observed five 
major complexes of which certain species was found to be closely related to each other. 
These complexes were assigned a “colour” and can be found in the appendix of this paper.  
They went on to state that the red and orange complexes were strikingly related to each other 
and to the clinical measures of periodontal disease. These “red and orange complex” bacteria 
as well as Aggregatibacter actinomycetemcomitans (A.a) have been found in higher 
proportions around diseased implants,46, 47, 59 which indicates a predominance of gram 
negative, anaerobic species in a “diseased state”. 
A recent systematic review describing the microbiota of peri-implant diseases,48 concluded 
that the microbiological profile around diseased implants is mixed (both gram positive and 
negative), highly variable but predominated by gram negative anaerobic bacteria. Other 
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species not normally associated with periodontitis have also been reported, with higher 
proportions of species such as Fusobacterium spp., Campylobacter spp., Staphylococci spp. 
and Peptostreptococci spp.49, 50 This is also in agreement with our findings with these bacteria 
(grouped according to complexes green and yellow) also observed in the submucosal peri-
implant pockets. Our baseline microbiological characteristics demonstrated a polymicrobial 
infection predominated by members of the orange complex. Members of the red complex 
were found at the lowest frequency.  Although, no comparison in microbiological species with 
disease-free implants was attempted, our results are in agreement with the study by Shibli et 
al which demonstrated a submucosal microbiota in cases of peri-implantitis dominated by 
species of the orange complex.59 In contrast to our study, they also demonstrated high 
numbers of red complex species which may relate to the differences in methodology 
employed. It is important to note, that the patients recruited in our study were periodontally 
healthy or where applicable were treated for periodontal disease prior to commencement. 
This was conducted in order to establish baseline levels of plaque and minimise the 
possibility of residual periodontal pockets harbouring pathogens that can trans-locate to 
implant surfaces. Pre-treatment of periodontitis would be expected to have an impact on the 
overall bacterial count and species that were able to be detected at baseline. 
 
A limitation of the current study was that we predominately relied on culturing techniques to 
determine bacteria counts and identification.  However using bacterial counts to monitor 
disease progression or response to a therapy can be problematic because the direct causal 
relationship between the numbers of offending bacteria in peri-implantitis has yet to be 
demonstrated. This was observed in our study with the large variations in counts seen 
between and within subjects. 
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In the current study, if our culture techniques were unsuccessful in identification of bacteria, 
molecular (PCR) analysis was employed. It should be noted that this was conducted on 
specimens that were only cultivatable and therefore our results reflect total and means of 
viable bacteria found. Bacterial counts and the species analysed may have been 
underestimated. Charalampakis et al analysed the microbiological characteristics of peri-
implantitis by utilising both culture and molecular techniques (checkerboard DNA-DNA 
hybridization analysis).175 They found that culture failed to identify certain target bacterial 
species in approximately 19% of the cases whist the checkerboard technique failed in only 
0.7% of cases. In our study, sampling and transportation times were tightly monitored and 
samples were always collected by laboratory staff and prepared for culture immediately on 
site. This would expect to increase the chance of bacteria survival and maintenance of their 
viability.  
 
10.3 Concentration of azithromycin 
 
A study by Malizia et al compared the tissue distribution of azithromycin in patients 
undergoing surgery involving third molar removal.107 They demonstrated elevated levels of 
azithromycin (500mg over 3 days) in gingival tissues compared to that found in saliva, plasma 
and bone. However, it should be noted that these were dissected gingival tissue samples. 
In our study using a disc diffusion bioassay, no zones of inhibition were shown from the 
samples taken by the methodology we used. The technique described by Driscoll et al,172 was 
originally applied to specimens derived from urine, serum or plasma. However, our study took 
specimens from the peri-implant crevicular fluid (PICF). We suggest that the amount of 
azithromycin (within the PICF if present) was too low or diluted to be detected with this 
methodology. Originally 50 µl of each 200µl sample was set aside for this analysis, of which 
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only 10µl was utilized in the inoculation of the discs to be used in the disc diffusion assay. 
The level of the dilution of the sample may have resulted in the levels of azithromycin being 
undetectable by our methodology. We would recommend further study in finding appropriate 
methodologies in determining azithromycin concentrations from the PICF. Perhaps a pre- 
study run to establish a suitable dilution would have been helpful with the benefit of hindsight.  
 
10.4 Cytokine Il-1β 
 
This study demonstrated a sustained decrease in the IL-1β cytokine levels following our 
therapy throughout the six month study period. This was reflected in the mean levels and the 
change in mean levels of IL-1β from baseline observed in both groups. Despite no statistical 
significant differences observed between groups, there was a trend for a larger decrease in 
IL-1β, as well as a greater frequency of subjects seen as “positive responders” in those 
allocated azithromycin. 
Cytokines are a group of soluble proteins that are non-specific mediators of inflammatory 
reactions which exert their immunomodulatory effects by regulating the growth, differentiation 
and transport of a wide array of host cells. IL-1β is one such example of a pro-inflammatory 
cytokine which is an important mediator of the host immune response to infection and has 
been shown to be upregulated in cases of peri-implantitis.37 Kao et al analysed the levels of 
the cytokine IL-1β in implants with peri-implantitis from samples taken from the peri-implant 
crevicular fluid.32 Interestingly, when IL-1β levels were compared between healthy and 
diseased implants, they were nearly four times higher around diseased implants. The levels 
around diseased implants were not only significantly higher than in healthy controls, but the 
levels of IL-1β in these healthy sites was consistently low. Similar trends were also 
demonstrated by Panagakos et al and Casado et al.33, 34 This is in agreement with the 
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findings of our study which demonstrated elevated levels of IL-1β in all cases of peri-
implantitis compared to healthy controls. 
Similar to the studies by Kao et al and Casado et al mentioned above, our study also 
demonstrated a high variability in IL-1β levels between patients resulting in large standard 
deviations. Much like the microbiological analysis, this impacted on the ability to obtain 
statistical significance which again may be improved with higher subject numbers. 
There is very limited data on the effect of non-surgical therapy on peri-implantitis with regards 
to changes in cytokine levels. Bassetti et al sought to determine the effect of two non-surgical 
treatment modalities on the levels of various cytokines including IL-1β.72 They observed 
significant reductions in IL-1β from baseline levels in both treatment groups which is in 
accordance with our findings. The current study demonstrated that the magnitude of change 
in the reduction of IL- 1β levels in the azithromycin group appeared larger across all time 
points compared to the control group however no statistical significance between groups was 
actually observed.  
An analysis was conducted to determine the effect of time on IL-1β levels. This is conducted 
in order to see if time rather than the actual treatment affected the outcome. A statistical 
significant effect of time was observed across all patients. This was most likely due to one 
patient (patient 5) having a very high level of IL-1β at baseline which skewed the result for the 
effect of time on the outcome. Otherwise, no statistical significant effect of time was observed 
within each treatment group for IL-1β levels. An analysis of the number of patients who 
demonstrated a decrease in microbiological and immunological parameters from baseline 
was also conducted. These patients were seen as “positive responders”. Of interest, it was 
observed that the majority of subjects who were positive responders belonged to the 
azithromycin group across the time points. 
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11.0 Conclusion 
 
Early studies were able to demonstrate a causal relationship between plaque and peri-
implant disease development in humans,19 which was further extrapolated to peri-implantitis 
in the animal model.25, 26 These studies illustrated the host response to the accumulation of 
plaque around dental implants. 
 It was noted that the reductions and subsequent rebound observed in the immunological 
data closely correlated with that of the microbiological data in our study. Despite reductions in 
levels of IL-1β initially after treatment, the levels gradually rebounded throughout the course 
of the study. Throughout all time points, IL-1β did not return to baseline levels, which was 
likely the result of the therapy as well as the ongoing management of the subjects’ oral 
hygiene.  Similarly, a reduction in microbiological parameters was initially seen post therapy 
with a trend for a gradual rebound in counts seen over time.  
It appears our study is consistent with the widely accepted hypothesis that peri-implant 
disease is the result of the host inflammatory response as a reaction to pathogenic bacteria 
and their products found within dental plaque. Further to this, the resultant signs arise due to 
interactions between the bacteria, bacterial products, the biological mediators of inflammation 
and host cells with the outcome dependant on the nature and the degree of the inflammatory 
response. As the time from therapy increased, we saw a gradual rebound in primary outcome 
measures which coincided with a recolonization of bacteria in the peri-implant pocket. This is 
demonstrated by the close correlations seen between microbiological and immunological 
parameters followed over 6 months. 
 
 120 
  
Within the limitations of this double blind placebo controlled randomised trial, despite a trend 
for a greater and a more sustained magnitude of change in outcome measures for subjects’ 
allocated azithromycin, no statistically significant effect was observed between treatment 
groups. We demonstrated that the response to non-surgical treatment, with or without 
adjunctive azithromycin is highly variable and unpredictable with gradual rebound in 
immunological and microbiological parameters seen after 6 months. Because of the limited 
number of patients recruited, no definitive conclusions can be made. There is clear indication 
that further longitudinal research into the effects of azithromycin at peri-implant-host interface 
is warranted. 
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13.0 Appendix 
Table a. illustrates the species of bacteria analysed and grouped according to microbial 
complexes.45 
Table a. Species of bacteria according to microbial complexes. 
Red Orange Purple Yellow Green 
Tannerella 
forsythia 
Fusobacterium 
nucleatum 
Actinomyces 
odontolyticus 
Streptococcus 
mitis 
Aggregatibacter 
actinomycetemco
mitans 
Porphyromonas 
gingivalis 
Peptostreptococcus 
micros 
Veillonella 
parvula 
Streptococcus 
oralis 
Capnocytophaga 
spp. 
Treponema 
denticola 
Prevotella 
intermedia 
 Streptococcus 
sanguinis 
Campylobacter 
concisus 
 Prevotella 
nigrescens 
  Eikenella 
corrodens 
 Streptococcus 
constellatus 
   
 Campylobacter 
gracilis 
   
 Campylobacter 
rectus 
   
 Campylobacter 
showae 
   
 Eubacterium 
nodatum 
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Table b. shows the total viable count (TVC) of aerobic bacteria in the azithromycin group 
cultured from submucosal samples at 6 different time points (expressed as CFU/ml  x106). 
*One patient was lost to follow up (patient 5 at day 180) in the azithromycin group. This 
patient failed to attend the last appointment and did not return phone calls. Data from this 
patient at Day 180 was not included in the analysis of means. 
 
Table b. Aerobic total viable count per patient in the azithromycin group  
Patient Day 1 Day 3 Day 7 Day 21 Day 90 Day 180 
1 0.1 0.15 1.1 1.05 8 70 
3 55 8 100 180 4.76 0.0095 
5 400 2.8 0.42 1 16 * 
7 36 0.3 0.23 0.02 0.55 0.01 
9 1.76 0.0025 1.48 100 2.16 0.6 
12 24 0.34 24 0.062 16.2 6 
14 1.28 0.68 1.9 0.32 72 1.46 
15 24 8.6 16 12 15.5 1000 
17 159 400 93 2 15.4 26.4 
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Table c. shows the total viable count (TVC) of aerobic bacteria in the placebo group cultured 
from submucosal samples at 6 different time points expressed as CFU/ml- x106. 
 
Table c. Aerobic total viable count per patient in the placebo group  
Placebo Day 1 Day 3 Day 7 Day 21 Day 90 Day 180 
2 0.06 3 0.2 12 0.6 55 
4 3.4 50 36 120 360 480 
6 460 36 80 0.44 75 1.84 
8 1 1.2 0.45 3.2 1 1.86 
10 224 104 1.05 368 19.2 2.6 
11 0.45 0.14 0.14 0.09 2.8 1.71 
13 4.8 288 70 48 400 133 
16 66 51.6 0.6 48 54 36.8 
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Table d. shows the total viable count (TVC) of anaerobic bacteria in the azithromycin group 
cultured from submucosal samples at 6 different time points expressed as CFU/ml x106. 
 
Table d. Anaerobic total viable count per patient in the azithromycin group  
Patient Day 1 Day 3 Day 7 Day 21 Day 90 Day 180 
1 1.5 0.4 1.15 1 160 480 
3 600 21 120 400 12 2.8 
5 600 2.8 0.44 2 24 * 
7 56 0.25 0.3 0.11 2.8 0.03 
9 160 1 2.8 360 4.8 1.2 
12 56 0.54 22 1.09 25 32.4 
14 12 6.52 0.96 0.18 265 1.34 
15 140 40 163 25 24 800 
17 400 436 250 45.6 23 31.2 
*Patient 5 at day 180 was lost to follow up. 
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Table e. shows the total viable count (TVC) of anaerobic bacteria in the placebo group 
cultured from submucosal samples at 6 different time points expressed as CFU/ml x106. 
 
Table e. Anaerobic total viable count per patient in the placebo group  
Patient Day 1 Day 3 Day 7 Day 21 Day 90 Day 180 
2 0.1 3.5 0.15 10 0.6 22 
4 0.25 104 48 680 800 1000 
6 1080 48 160 1.5 160 2.56 
8 20 2 1.2 280 2.08 144 
10 480 448 2.2 1440 680 86 
11 0.39 0.14 0.18 0.27 136 5.4 
13 36 1000 400 420 1000 1000 
16 480 276 1.6 155 240 112 
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Table f. shows the change in aerobic total viable count from baseline expressed as CFU/ml 
x106 for the azithromycin group. Baseline was taken at day 1/pre treatment. Negative values 
indicate a decrease in counts below baseline levels. Data from patient 5 (day 180) was not 
included in the analysis of mean changes. 
 
Table f. Changes from baseline in the azithromycin group for aerobic bacteria  
Patient Day 3 Day 7 Day 21 Day 90 Day 180 
1 0.05 1 0.95 7.9 69.9 
3 -47 45 125 -50.24 -54.9905 
5 -397.2 -399.58 -399 -384 * 
7 -35.7 -35.77 -35.98 -35.45 -35.99 
9 -1.7575 -0.28 98.24 0.4 -1.16 
12 -23.66 0 -23.938 -7.8 -18 
14 -0.6 0.62 -0.96 70.72 0.18 
15 -15.4 -8 -12 -8.5 976 
17 241 -66 -157 -143.6 -132.6 
*Patient 5 at day 180 was lost to follow up.  
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Table g. shows the change in total viable aerobic bacteria counts from baseline expressed as 
CFU/ml x106 for the placebo group. Baseline was taken at day 1 pre treatment.  
 
Table g. Changes from baseline in the placebo group for aerobic bacteria 
Placebo Day 3 Day 7 Day 21 Day 90 Day 180 
2 2.94 0.14 11.94 0.54 54.94 
4 46.6 32.6 116.6 356.6 476.6 
6 -424 -380 -459.56 -385 -458.16 
8 0.2 -0.55 2.2 0 0.86 
10 -120 -222.95 144 -204.8 -221.4 
11 -0.31 -0.31 -0.36 2.35 1.26 
13 283.2 65.2 43.2 395.2 128.2 
16 -14.4 -65.4 -18 -12 -29.2 
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Table h. shows the change in anaerobic total viable count from baseline expressed as 
CFU/ml x106 for the azithromycin group. Baseline was taken at day 1/pre treatment. 
 
Table h. Change from baseline in the azithromycin group for anaerobic bacteria  
Patient Day 3 Day 7 Day 21 Day 90 Day 180 
1 -1.1 -0.35 -0.5 158.5 478.5 
3 -579 -480 -200 -588 -597.2 
5 -597.2 -599.56 -598 -576 * 
7 -55.75 -55.7 -55.89 -53.2 -55.97 
9 -159 -157.2 200 -155.2 -158.8 
12 -55.46 -34 -54.91 -31 -23.6 
14 -5.48 -11.04 -11.82 253 -10.66 
15 -100 23 -115 -116 660 
17 36 -150 -354.4 -377 -368.8 
*Patient 5 at day 180 was lost to follow up. 
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Table i. shows change in anaerobic total viable count from baseline expressed as CFU/ml 
x106 for the placebo group. Baseline was taken at day 1/pre treatment. 
 
Table i. Change from baseline in the placebo group for anaerobic bacteria  
Patient Day 3 Day 7 Day 21 Day 90 Day 180 
2 3.4 0.05 9.9 0.5 21.9 
4 103.75 47.75 679.75 799.75 999.75 
6 -1032 -920 -1078.5 -920 -1077.44 
8 -18 -18.8 260 -17.92 124 
10 -32 -477.8 960 200 -394 
11 -0.25 -0.21 -0.12 135.61 5.01 
13 964 364 384 964 964 
16 -204 -478.4 -325 -240 -368 
 
  
 147 
  
Table j. demonstrates the IL-1β levels (expressed as pg/ml) for the subjects in the 
azithromycin group across the six time points of the study. A level of zero was observed for 
subject 1 at day 3 which indicated levels of IL-1β below the detection limit. 
 
Table j. IL-1β levels for the azithromycin group. 
Patient Day 1 Day 3 Day 7 Day 21 Day 90 Day 180 
1 8.481 0 4.514 3.813 17.307 6.866 
3 58.354 48.217 57.224 19.940 9.431 23.119 
5 502.619 17.307 34.750 86.007 69.499 * 
7 29.107 99.134 25.410 6.866 10.680 47.656 
9 48.778 23.406 11.605 11.298 3.094 35.874 
12 225.922 26.268 13.734 26.266 27.688 6.537 
14 19.066 18.188 10.680 10.680 14.336 8.161 
15 28.823 15.828 21.678 12.522 13.130 27.688 
17 107.983 59.208 46.533 36.998 27.404 14.035 
 *Patient 5 at day 180 was lost to follow up. Data from this patient at Day 180 was not 
included in the analysis of means. 
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Table k. demonstrates the IL-1β levels (expressed as pg/ml) for the subjects in the placebo 
group across the six time points of the study. 
 
Table k.  IL-1β levels for the placebo group. 
Placebo 1 3 7 21 90 180 
2 142.920 27.688 10.989 7.840 3.813 23.693 
4 13.734 37.559 18.481 47.656 36.717 31.651 
6 47.094 83.069 73.478 113.873 39.243 33.061 
8 225.922 41.767 17.601 41.206 16.717 137.278 
10 62.321 20.520 106.445 58.637 41.486 27.972 
11 145.940 4.514 88.369 49.621 97.022 102.471 
13 38.121 35.031 45.411 30.804 40.645 35.874 
16 11.298 14.934 12.522 16.421 12.827 19.649 
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Table l. demonstrates the changes in IL-1β levels from baseline expressed as pg/ml for the 
azithromycin group. Baseline was taken at day 1/pre-treatment levels. Data from patient 5 
(day 180) was not included in the analysis of the means. 
 
Table l. IL-1β changes from baseline in the azithromycin group. 
Patient Day 3 Day 7 Day 21 Day 90 Day 180 
1 -8.481 -3.967 -4.667 8.826 -1.615 
3 -10.137 -1.130 -38.415 -48.924 -35.236 
5 -485.312 -467.869 -416.612 -433.120 * 
7 70.027 -3.696 -22.241 -18.427 18.549 
9 -25.373 -37.173 -37.481 -45.684 -12.904 
12 -199.657 -212.188 -199.657 -198.234 -219.385 
14 -0.878 -8.386 -8.386 -4.730 -10.905 
15 -12.995 -7.145 -16.301 -15.693 -1.135 
17 -48.780 -61.449 -70.985 -80.579 -93.947 
*Patient 5 at day 180 was lost to follow up 
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Table m. demonstrates the changes in IL-1β levels from baseline expressed as pg/ml for the 
placebo group. 
 
Table m. IL-1β changes from baseline in the placebo group. 
Patient Day 3 Day 7 Day 21 Day 90 Day 180 
2 -115.232 -131.931 -135.080 -139.107 -119.228 
4 23.825 4.747 33.922 22.983 17.917 
6 35.974 26.383 66.779 -7.852 -14.034 
8 -184.156 -208.321 -184.716 -209.206 -88.645 
10 -41.801 44.124 -3.684 -20.835 -34.349 
11 -141.426 -57.571 -96.319 -48.917 -43.469 
13 -3.090 7.291 -7.317 2.525 -2.246 
16 3.637 1.225 5.123 1.529 8.351 
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Invitation 
You are invited to participate in a research study into the effects of debridement (physical 
removal of the bacterial contamination) around your implant (s) and crown or bridge or 
denture with or without the help of antibiotics. 
 
The study is being conducted by: 
A/Prof Stephen Yeung, Dept of Periodontics, Faculty of Dentistry. The University of Sydney 
and the Westmead Centre for Oral Health. 
A/Prof Axel Spahr, Dept of Periodontics, Faculty of Dentistry. The University of Sydney. 
Dr. Alex Kalos, Dept of Periodontics, Faculty of Dentistry. The University of Sydney, 
Westmead Centre for Oral Health and Sydney Dental Hospital. 
Dr. Leon Gershenfeld, Dept of Periodontics, Faculty of Dentistry. The University of Sydney, 
Westmead Centre for Oral Health and Sydney Dental Hospital. 
 
 
Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why the research is being done and what it will involve. Please take the time to 
read the following information carefully and discuss it with others if you wish. 
 
What is the purpose of the study? 
 
The beneficial effect of antibiotics (such as Azithromycin) on infections involving the 
gum around teeth has been well documented. Research indicates a greater healing 
capacity of the gum when antibiotics are used as an adjunct to mechanical scaling 
and cleaning around the tooth. This scaling and cleaning refers to the standard clean 
one would have when visiting the dentist for a check up. 
We hypothesize that similar beneficial effects around the tissues of diseased implants 
can also be achieved when in combination with this mechanical cleaning. The 
proposed study aims to establish a Proof of Concept that the treatment of this 
antibiotic as an adjunct to mechanical cleaning is effective in the treatment of the 
infected tissues around diseased implants.  
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Who will be invited to enter the study? 
You are invited to participate in this study because you may be suffering from an infection 
around your implant(s). This is termed peri-implantitis. 
This is a condition which results in inflammation and infection around your dental implant and 
can lead to the eventual loss of the implant. 
Do you have a choice? 
Participation in this study is voluntary. It is completely up to you whether or not you 
participate. If you decide not to participate, it will not affect the treatment you receive now or 
in the future. Whatever your decision, it will not affect your relationship with the staff caring for 
you. New information about the treatment being studied may become available during the 
course of the study. You will be kept informed of any significant new findings that may affect 
your willingness to continue in the study. If you wish to withdraw from the study once it has 
started, you can do so at any time without having to give a reason. 
What will happen on the study? 
If you agree to participate in this study, you will be asked to sign the Participant 
Consent Form. 
This study will be conducted over 6 months. 
If you agree to participate in this trial, you will then be asked to undergo the following 
procedures 
 
 You will be initially diagnosed with peri-implantitis.  
 Upon diagnosis and as soon as practical, you will be randomly allocated into one of 
two groups as this is a randomized trial (see below for definition). 
 Clinical measurements will be conducted around the implant along with photos of the 
area in question. The measurements involve the use of a standard dental probe 
dipped below the gum line which will enable the researcher to measure the extent of 
implant disease. 
 Apart from doing clinical measurements, we will also collect some fluid around the 
gum (gingival crevicular fluid) and a plaque sample to test the level of bacteria, using 
filter paper strips to blot up this fluid. This procedure is NOT painful and has no impact 
on your health or comfort.  
Plaque samples will be taken with a sterile paper point. 
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These samples will be tested in a laboratory by the following methods 
 
 Culture and/or molecular biological techniques – to analyse the type of specific 
bacteria around your dental implant 
 ELISA testing – to analyse the presence of inflammation cells and the amount of 
antibiotic in the gum fluid. 
You will not be required to be present for these laboratory tests. 
 
Group 1 will receive the mechanical cleaning and a placebo (see below for definition) 
(Treatment 1) 
Group 2 will receive the mechanical cleaning and an antibiotic tablet (Azithromycin) 
(Treatment 2) 
 
You will need to continue to take one tablet per day for the following three days no matter 
which group you are in. 
The allocation of the tablet will be done in a random fashion and the researcher will not know 
what treatment you will be having. The researcher and the participant will be “blind” to the 
treatment group you are in (see below for definition). 
 
Definitions: 
‘Placebo’: A placebo is a dummy treatment that looks like the genuine medicine but contains 
no active ingredient.  
‘Randomised trial’: Sometimes doctors don’t know the best way of treating patients with a 
particular condition so comparisons need to be made between different treatments. To do 
this, study participants are put into groups and given different treatments, and the results are 
compared to see whether one treatment is better. To ensure the groups are similar to start 
with, a computer allocates each study participant into a group randomly, like the flip of a coin. 
Neither the doctor nor the study participant can decide which treatment the participant 
receives. 
‘Blind trial’: In a “blind trial” the study participants do not know which treatment group they are 
in. If the trial is “double blind”, neither the doctor nor the study participant knows which 
treatment the participant is receiving (although, if the doctor needs to find out, he can do so). 
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In addition, the researchers would like to have access to your medical record to obtain 
information relevant to the study.  
 
The table below summarises the procedures and days required to be present for examination 
and testing as well as an approximate time needed for each appointment. 
 
Day Procedure Time Required  
Day   1 Initial Examination  
1. Examination and consultation 
2. Informed Consent  
3. Diagnosis and Treatment plan 
 
Clinical Diagnostics Tests and 
measurements 
4. Photos 
5. Clinical  measurements 
 
Biological Tests 
6. Gum Fluid (GCF) sampling 
7. Plaque Sample  
8. Cleaning around the implant 
9. To take tablet 
 
 
Total Time Requited: 1 
hour 
Day 1 – 
1 hour 
later 
Biological Tests 
 GCF sampling 
 Plaque Sample  
 
 To take tablet 
15 minutes  
 
2  
 To take tablet (appointment 
required) 
5 minutes 
3  
 To take tablet (appointment 
required) 
 
Biological Tests 
 GCF sampling 
 Plaque Sample  
15 minutes 
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7 Repeat Clinical Diagnostics Tests and 
measurements 
 Photos 
 Clinical measurements 
  
Biological Tests 
 GCF sampling 
Plaque Sample  
 
 
35 minutes  
21 Clinical Diagnostics Tests  
 Photos  
Clinical measurements  
 
Biological Tests 
 GCF sampling 
 Plaque Sample  
Time Required : 
40 minutes 
90 ( 3 
months) 
Clinical Diagnostics Tests  
 Photos  
 Clinical Measurements 
 
 
Biological Tests 
 GCF sampling 
 Plaque Sample  
 
Time Required : 
40 minutes 
180 ( 6 
months) 
Clinical Diagnostics Tests  
 
 Photos 
 Clinical Measurements 
 
Biological Tests 
 
 GCF sampling 
 Plaque Sample  
Time Required : 
40 minutes 
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What will happen to my tissue sample after it has been used? 
The gum fluid and plaque sample/s you provide during the study will be destroyed at the 
completion of the study. The researchers will not store your sample. 
 
What will happen to my sample after it has been tested? 
Your sample will only be used for the purpose of this research study. Samples you provide 
during the study will be destroyed at the completion of the study 
 
Will I be able to get my sample back if I want? 
It will not be appropriate in all circumstances to return your sample, for example where this 
may pose an infectious risk.  
 
Are there any risks? 
All medical procedures involve some risk of injury. In addition, there may be risks associated 
with this study that are presently unknown or unforeseeable. In spite of all reasonable 
precautions, you might develop medical complications from participating in this study. The 
known risks of this study are: 
 
From the antibiotic intake as part of the treatment 
 Diarrhoea (5%) 
 Nausea  (3%) 
 
The following possible side effects occur rarely and are all known to occur less that 1% of the 
time from intake of the antibiotic. 
 Vomiting   
 Skin reactions           
 Pseudomembranous colitis (infection in the colon)  
 Anaphylactic/Allergic reaction  
       
 
 
PARTICIPANT INFORMATION SHEET AND CONSENT FORM 
 
Study Title:   The effect of Azithromycin on the treatment of peri-implant infection 
 
157 
Version No 2 Dated 10/12/12                                                                   
 Chest palpitations/pain  
 Dizziness/headaches and fatigue  
 Loss of appetite  
 Pain in the Joints 
 Inflammation of the vagina 
 Fainting or seizures 
 Tongue discolourations or Thrush infections 
 Insomnia 
 Liver or kidney disorders 
 
From the mechanical cleaning 
 Mild discomfort around the gum that may last for up to one week. 
 
There are no additional risks involved in participating in this study.  
 
Pregnancy and contraception 
 
It is important that women participating in this study are not pregnant and do not become 
pregnant during the study as the use of an antibiotic may damage an unborn baby. The effect 
of azithromycin on an unborn baby is unknown.  
 
Some antibiotics like azithromycin can be expressed in breast milk, therefore if you are breast 
feeding please advice the researchers as you will not be able to participate in this study. You 
will be advised as to the best course of care for your treatment. 
 
Please be aware that the antibiotic azithromycin may reduce the effectiveness of the oral 
contraceptive pill in females for up to 7 days after the cessation of treatment. It is advised that 
another form of contraception be used during this time period. 
If at any time you think you, or your sexual partner may be pregnant, it is important to let the 
researchers know immediately. 
 
Are there any benefits? 
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This study aims to further medical knowledge and may improve future treatment of peri-
implant diseases; however it may not directly benefit you. 
Currently there is no gold standard of treatment for peri-implant disease and therefore much 
research is required into potential therapies for this condition. 
Several cases have documented the control of bacteria responsible for periodontal disease 
(loss of the support structure around teeth) after administration of antibiotics in accordance 
with mechanical cleaning, with subsequent resolution of disease. 
However there are little studies available that have documented this effect around dental 
implants. 
It is thus the purpose of this study to observe whether such effects can be replicated around 
dental implants with obvious potential benefits to patients and society as a whole. 
 
Based on evidence of this antibiotic in cases of gum disease (periodontal disease) the 
researchers believe it may be of benefit to patients with your similar but not exact condition 
around dental implants. As there is no gold standard to treatment of this condition (peri-
implant disease) and because individuals respond differently to therapy, no one in advance 
can know if it will be helpful in your particular case 
 
Confidentiality/ Privacy 
Of the people treating you, only those named above or necessary others e.g. all nursing staff 
involved in your care will know whether or not you are participating in this study. Any 
identifiable information that is collected about you in connection with this study will remain 
confidential and will be disclosed only with your permission, or except as required by law. 
Only the researchers named above will have access to your details and results that will be 
held securely at the Westmead Centre for Oral Health. 
Your sample will not be linked to your name or any personal details. The link between this 
information and your sample will be removed before your sample is analysed. Your test 
results will not be linked to you. 
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Compensation   
 
If you suffer any injuries or complications as a result of this study, you should contact the 
study doctor as soon as possible, who will assist you in arranging appropriate medical 
treatment. You may have a right to take legal action to obtain compensation for any injuries or 
complications resulting from the study. Compensation may be available if your injury or 
complication is sufficiently serious and is caused by unsafe drugs or equipment, or by the 
negligence of one of the parties involved in the study (for example, the researcher, the 
hospital, or the treating doctor). If you receive compensation that includes an amount for 
medical expenses, you will be required to pay for your medical treatment from those 
compensation monies. You do not give up any legal rights to compensation by participating in 
this study. 
If you are not eligible for compensation for your injury or complication under the law, but are 
eligible for Medicare, then you can receive any medical treatment required for your injury or 
complication free of charge as a public patient in any Australian public hospital. 
 
Will taking part in this study cost me anything, and will I be paid? 
Participation in this study will not cost you anything. You will not however be reimbursed for 
your time. 
 
What will happen at the conclusion of the study?   
The treatment will not be available to you after the study finishes. 
This decision will be made in consultation between you and your treating doctor about the 
most appropriate treatment for you at that time of completion of the study if required. 
 
What happens with the results? 
If you give us your permission by signing the consent document, we plan to discuss/publish 
the results.  
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The information will be presented in the form of the results obtained from the study conducted 
and may be discussed in peer-reviewed journals, presentations at conferences or other 
professional forums. 
In any publication, information will be provided in such a way that you cannot be identified. 
Results of the study will be provided to you, if you wish. 
 
What if I don’t want to know the results? 
It is entirely your decision as to whether or not you decide to be told the results. 
This will not affect the treatment you receive now or in the future. 
 
Complaints 
This study has been approved by Western Sydney Local Health District Human Research 
Ethics Committee.  If you have any concerns about the conduct of the study, or your rights as 
a study participant, you may contact: 
Ms Jillian Gwynne Lewis, Westmead and Research Governance Officer, (Contact details:  
Telephone No 9515 6766 Email address:  jillian.lewis@swahs.health.nsw.gov.au). 
 
Contact details 
When you have read this information, the researchers Drs. Alex Kalos and Leon Gershenfeld 
will discuss it with you and any queries you may have. If you would like to know more at any 
stage, please do not hesitate to contact them on (02) 9845 7425. If you have any problems 
while on the study, please contact one of these two numbers 
 
Dr Alex Kalos 
Working hours Telephone No – (02) 9845 7425 
After hours Telephone No - 0402 081 686 
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Dr. Leon Gershenfeld 
Working hours Telephone No – (02) 9845 7425 
After hours Telephone No – 0412 483 442 
 
Thank you for taking the time to consider this study. 
 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
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CONSENT TO PARTICIPATE IN RESEARCH 
Name of Researchers: Drs. Alex Kalos and Leon Gershenfeld 
 
1. I understand that the researcher will conduct this study in a manner conforming to ethical and 
scientific principles set out by the National Health and Medical Research Council of Australia and 
the Good Clinical Research Practice Guidelines of the Therapeutic Goods Administration. 
 
2. I acknowledge that I have read, or have had read to me the Participant Information Sheet relating 
to this study.   I acknowledge that I understand the Participant Information Sheet.  I acknowledge 
that the general purposes, methods, demands and possible risks and inconveniences which may 
occur to me during the study have been explained to me by ____________________________ 
(“the researcher”) and I, being over the age of 16 acknowledge that I understand the general 
purposes, methods, demands and possible risks and inconveniences which may occur during the 
study. 
 
3. I acknowledge that I have been given time to consider the information and to seek other advice. 
 
4. I acknowledge that refusal to take part in this study will not affect the usual treatment of my 
condition. 
 
5. I acknowledge that I am volunteering to take part in this study and I may withdraw at any time. 
 
6. I acknowledge that this research has been approved by the Western Sydney Local Health District 
Human Research Ethics Committee. 
 
7. I acknowledge that I have received a copy of this form and the Participant Information Sheet, which 
I have signed. 
 
8. I acknowledge that any regulatory authorities may have access to my medical records relevant to 
this study to monitor the research in which I am agreeing to participate.  However, I understand my 
identity will not be disclosed to anyone else or in publications or presentations.   
 
Before signing, please read ‘IMPORTANT NOTE’ following. 
IMPORTANT NOTE: 
This consent should only be signed as follows: 
1. Where a participant is over the age of 16 years, then by the participant personally. 
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Name of participant _____________________________   Date of Birth _____________________ 
Address of participant ________________________________________________________ 
Signature of participant _________________________________ Date: ____________________   
Signature of researcher _________________________________ Date: ____________________ 
Signature of witness ___________________________________    Date: __________________ 
 
